Composition for treatment of undifferentiated gastric cancer

ABSTRACT

Disclosed are: a therapeutic agent, a kit and a treatment method for undifferentiated gastric cancer; and a pharmaceutical composition, a kit and a treatment method which are more effective on a living organism having at least one cell selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing a mutant FGFR2. A combination of a FGFR2 inhibitor and a therapeutic substance for gastric cancer is more effective on undifferentiated gastric cancer. The combination of a FGFR2 inhibitor and a therapeutic substance for gastric cancer is more effective on a living organism having at least one cell selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing a mutant FGFR2.

FIELD OF THE INVENTION

The present invention relates to a therapeutic agent, a kit and a therapeutic method for undifferentiated gastric cancer. The therapeutic agent comprises a combination of a substance having the activity of inhibiting the kinase activity of a fibroblast growth factor receptor 2 (hereinafter also referred to as “FGFR2”) and a therapeutic substance for gastric cancer or a FGFR2 inhibitor different from the former FGFR2 inhibitor. The substance having such inhibitory activity is hereinafter also referred to as a “FGFR2 inhibitor”. The present invention relates to use of a FGFR2 inhibitor for producing the therapeutic agent and to a FGFR2 inhibitor for the therapeutic agent.

In addition, the present invention relates to a pharmaceutical composition and a kit comprising a combination of a FGFR2 inhibitor for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2 and a therapeutic substance for gastric cancer or a FGFR2 inhibitor different from the former FGFR2 inhibitor, to a therapeutic method for a disease characterized by administering effective dosages of a FGFR2 inhibitor and a therapeutic substance for gastric cancer or a FGFR2 inhibitor different from the former FGFR2 inhibitor to the living organism, to use of a FGFR2 inhibitor for producing the pharmaceutical composition and to a FGFR2 inhibitor for the pharmaceutical composition.

BACKGROUND OF THE INVENTION

Gastric cancer is one of the major cancers that cause death. Gastric cancers are histopathologically classified into differentiated gastric cancers and undifferentiated gastric cancers, where the latter includes poorly differentiated adenocarcinoma, signet-ring cell carcinoma, mucinous carcinoma and the like.

In the case of undifferentiated gastric cancer, cancer cells are likely to diffuse and also likely to develop fibrosis that leads to scirrhous gastric cancer. Undifferentiated gastric cancer is commonly observed in young people, and is known to cause invasive proliferation and metastasis, indicating a poor prognosis⁽¹⁾.

FGFR2 (also referred to as “K-sam”) is amplified in diffuse-type gastric cancer, namely, undifferentiated gastric cancer and is known to be involved in malignant alteration of cancer^((1,2)). FGFR2 gene is reported to be amplified in 33% of patients with undifferentiated gastric cancer⁽²⁾, and FGFR2 is reported to be positive in about 50% of patients with undifferentiated gastric cancer FGFR2 gene induces transformation of NIH3T3 cell, and the transformed cell is reported to show tumorigenicity in nude mice⁽³⁾. Furthermore, FGFR2 truncated at C-terminal is reported to have a strong transformation activity and predominantly expressed in undifferentiated gastric cancer cell line^((1,3))). For example, FGFR2 having residues downstream from tyrosine at 769 deleted is reported to have a high transformation activity⁽³⁾.

It is also reported that FGFR2 gene is amplified in poorly differentiated gastric cancer, particularly scirrhous gastric cancer, while FGFR2 protein having C-terminal (including tyrosine residues 780, 784 and 813) deleted is specifically expressed in scirrhous gastric cancer⁽⁴⁾. Amplification of activated FGFR2 is reported to cause tumor growth in scirrhous gastric cancer⁽⁴⁾.

Examples of conventionally-used chemotherapeutic substances for gastric cancer include 5-fluorouracil analogs and paclitaxel analogs. None of them, however, have satisfactory anti-tumor effect and thus there has been a strong need for development of a novel anti-tumor agent.

A FGFR2 inhibitor, diphenylamine derivative, is recently reported to dose-dependently suppress cell growth of a human scirrhous gastric cell line and show anti-tumor effect on a subcutaneous transplanted (xenograft) model of human scirrhous gastric cell line⁽⁵⁾.

A FGFR2 inhibitor, 4-[(4-fluoro-2-methylindol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline, is suggested to be effective on gastric cancer overexpressing K-sam⁽⁶⁾.

Accordingly, a FGFR2 inhibitor is suggested to show antiproliferative action and anti-tumor effect on undifferentiated gastric cancers, preferably poorly differentiated adenocarcinoma, signet-ring cell carcinoma, mucinous carcinoma and scirrhous gastric cancer.

Here, a compound represented by General Formula (I) is known as an antiangiogenic substance⁽⁷⁻⁹⁾. However, there is no report that the compound represented by General Formula (I) has a FGFR2 inhibitory activity.

Moreover, there has been no report as to whether a combination of these compounds will bring any effect.

REFERENCES

-   (1) Clinical Cancer Research. 2(8), 1373-1381, 1996. -   (2) Journal of Cancer Research and Clinical Oncology. 127, 207-216,     2001. -   (3) Cancer Research. 54, 3237-3241, 1994. -   (4) Cancer Research. 59(24), 6080-6086, 1999. -   (5) Bioorganic and Medicinal Chemistry Letters. 14(4), 875-879,     2004. -   (6) Proceeding of the American Association for Cancer Research. 47,     890, 2006. -   (7) International Publication No. WO02/32872 -   (8) International Publication No. WO2004/080462 -   (9) International Publication No. WO2005/063713

DISCLOSURE OF THE INVENTION

The present invention was achieved regarding the circumstances described above and the problems to be solved by the invention are to provide a therapeutic agent, a kit and a therapeutic method for undifferentiated gastric cancer, and to provide a pharmaceutical composition, a kit and a therapeutic method which are more effective on a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

In order to solve the above problems, the inventors have gone through keen examination, as a result of which the inventors found that a compound represented by General formula (I), a pharmacologically acceptable salt thereof or a solvate thereof has a FGFR2 inhibitory activity. The inventors also found that a compound represented by General formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is more effective on undifferentiated gastric cancer. Furthermore, the inventors found that a compound represented by General formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is more effective on a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2. As a result of further research based on these findings, the inventors found that a compound represented by General formula (I), a pharmacologically acceptable salt thereof or a solvate thereof has a superior anti-tumor effect when used in combination with a therapeutic substance for gastric cancer as compared with that obtained with the therapeutic substance for gastric cancer alone in subcutaneous transplanted (xenograft) models (in vivo) of human scirrhous gastric cancer cell lines. Hence, a FGFR2 inhibitor, for example, a compound represented by General formula (I), a pharmacologically acceptable salt thereof or a solvate thereof appears to show an excellent anti-tumor effect when used in combination with a therapeutic substance for gastric cancer and thus found that a combination of a FGFR2 inhibitor and a therapeutic substance for gastric cancer may be used as an effective therapeutic agent and kit for undifferentiated gastric cancer, and for undifferentiated gastric cancer.

Thus, the present invention relates to the followings.

(1) A therapeutic agent for undifferentiated gastric cancer comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(2) A pharmaceutical composition for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, the pharmaceutical composition comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(3) A method for treating undifferentiated gastric cancer, characterized by administering effective dosages of a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof and a therapeutic substance for gastric cancer or a FGFR2 inhibitor to a living organism.

(4) A method for treating a disease, characterized by administering effective dosages of a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof and a therapeutic substance for gastric cancer or a FGFR2 inhibitor to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

(5) Use of a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof for producing a therapeutic agent for undifferentiated gastric cancer in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(6) Use of a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof for producing a pharmaceutical composition in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

(7) A compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof for treating undifferentiated gastric cancer in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(8) A compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof for administration in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

(9) A kit comprising:

(a) at least one selected from the group consisting of a packaging container, an instruction and a package insert describing use of a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor; and

(b) a therapeutic agent for undifferentiated gastric cancer comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof.

(10) A kit comprising:

(a) at least one selected from the group consisting of a packaging container, an instruction and a package insert describing use of a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor; and

(b) a pharmaceutical composition comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

(11) A kit characterized by a set of a therapeutic agent for undifferentiated gastric cancer comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof and a formulation comprising a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(12) A kit used for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, the kit characterized by a set of a formulation comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof and a formulation comprising a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(13) A therapeutic agent for undifferentiated gastric cancer comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof, characterized by administration to a living organism with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(14) A pharmaceutical composition for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, the pharmaceutical composition comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof, characterized by administration to the living organism with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

Furthermore, the present invention preferably relates to the followings.

(15) A therapeutic agent for undifferentiated gastric cancer comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(16) A pharmaceutical composition for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, the pharmaceutical composition comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(17) A method for treating undifferentiated gastric cancer, characterized by administering effective dosages of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof and a therapeutic substance for gastric cancer or a FGFR2 inhibitor to a living organism.

(18) A method for treating a disease, characterized by administering effective dosages of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof and a therapeutic substance for gastric cancer or a FGFR2 inhibitor to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

(19) Use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof for producing a therapeutic agent for undifferentiated gastric cancer in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(20) Use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof for producing a pharmaceutical composition in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

(21) 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof for treating undifferentiated gastric cancer in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(22) 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof for administration in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

(23) A kit comprising:

(a) at least one selected from the group consisting of a packaging container, an instruction and a package insert describing use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor; and

(b) a therapeutic agent for undifferentiated gastric cancer comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof.

(24) A kit comprising:

(a) at least one selected from the group consisting of a packaging container, an instruction and a package insert describing use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor; and

(b) a pharmaceutical composition comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

(25) A kit characterized by a set of a therapeutic agent for undifferentiated gastric cancer comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof and a formulation comprising a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(26) A kit used for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, the kit characterized by a set of a formulation comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof and a formulation comprising a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(27) A therapeutic agent for undifferentiated gastric cancer comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof, characterized by administration to a living organism with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(28) A pharmaceutical composition for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, the pharmaceutical composition comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof, characterized by administration to the living organism with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

The present invention also relates to the followings.

(29) A therapeutic agent for undifferentiated gastric cancer comprising a FGFR2 inhibitor in combination with a therapeutic substance for gastric cancer.

(30) A pharmaceutical composition for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, the pharmaceutical composition comprising a FGFR2 inhibitor in combination with a therapeutic substance for gastric cancer.

(31) A method for treating undifferentiated gastric cancer, characterized by administering effective dosages of a FGFR2 inhibitor and a therapeutic substance for gastric cancer to a living organism.

(32) A method for treating a disease, characterized by administering effective dosages of a FGFR2 inhibitor and a therapeutic substance for gastric cancer to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

(33) Use of a FGFR2 inhibitor or a therapeutic substance for gastric cancer for producing a therapeutic agent for undifferentiated gastric cancer in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(34) Use of a FGFR2 inhibitor or a therapeutic substance for gastric cancer for producing a pharmaceutical composition in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

(35) A FGFR2 inhibitor or a therapeutic substance for gastric cancer for treating undifferentiated gastric cancer in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(36) A FGFR2 inhibitor or a therapeutic substance for gastric cancer for administration in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

(37) A kit comprising:

(a) at least one selected from the group consisting of a packaging container, an instruction and a package insert describing combination use of a FGFR2 inhibitor and a therapeutic substance for gastric cancer; and

(b) a therapeutic agent for undifferentiated gastric cancer comprising a FGFR2 inhibitor or a therapeutic agent for gastric cancer comprising a therapeutic substance for gastric cancer.

(38) A kit comprising:

(a) at least one selected from the group consisting of a packaging container, an instruction and a package insert describing combination use of a FGFR2 inhibitor and a therapeutic substance for gastric cancer; and

(b) a pharmaceutical composition comprising a FGFR2 inhibitor or a therapeutic substance for gastric cancer for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

(39) A kit characterized by a set of a therapeutic agent for undifferentiated gastric cancer comprising a FGFR2 inhibitor and a formulation comprising a therapeutic substance for gastric cancer.

(40) A kit used for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, the kit characterized by a set of a formulation comprising a FGFR2 inhibitor and a formulation comprising a therapeutic substance for gastric cancer.

(41) A therapeutic agent for undifferentiated gastric cancer comprising a FGFR2 inhibitor or a therapeutic agent for gastric cancer comprising a therapeutic substance for gastric cancer, characterized by administration to a living organism with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

(42) A pharmaceutical composition for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, the pharmaceutical composition comprising a FGFR2 inhibitor or a therapeutic substance for gastric cancer characterized by administration to the living organism with a therapeutic substance for gastric cancer or a FGFR2 inhibitor.

More specifically, the present invention relates to the followings.

[1] A therapeutic agent for undifferentiated gastric cancer comprising a compound represented by General Formula (I) below, a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group]. [2] A therapeutic agent according to [1], wherein R¹ is a C₁₋₆ alkyl group (provided that R¹ may have at least one substituent selected from the group consisting of a 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, a C₁₋₆ alkoxy group, an amino group, a mono-C₁₋₆ alkylamino group and a di-C₁₋₆ alkylamino group which may have a C₁₋₆ alkyl group). [3] A therapeutic agent according to [1], wherein R¹ is a methyl group or a group represented by any one of the following formulae

(wherein, R^(a3) represents a methyl group; R^(a1) represents a hydrogen atom or a hydroxyl group; R^(a2) represents a methoxy group, an ethoxy group, a 1-pyrrolidinyl group, a 1-piperidinyl group, a 4-morpholinyl group, a dimethylamino group or a diethylamino group). [4] A therapeutic agent according to [1], wherein R¹ is a methyl group or a 2-methoxyethyl group. [5] A therapeutic agent according to [1], wherein R² is a cyano group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group). [6] A therapeutic agent according to [1], wherein R² is a cyano group or a group represented by Formula —CONHV^(a16) (wherein, V^(a16) represents a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₁₋₆ alkoxy group or a C₃₋₈ cycloalkoxy group, provided that V^(a16) may have at least one substituent selected from the group consisting of a halogen atom, a cyano group, a hydroxyl group and a C₁₋₆ alkoxy group). [7] A therapeutic agent according to [1], wherein R² is a group represented by Formula —CONHV^(a17) (wherein, V^(a17) represents a hydrogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group). [8] A therapeutic agent according to [1], wherein R² is a group represented by Formula —CONHV^(a18) (wherein, V^(a18) represents a hydrogen atom, a methyl group or a methoxy group). [9] A therapeutic agent according to [1], wherein Y¹ is a group represented by the following formula

(wherein, R⁷¹ represents a hydrogen atom or a halogen atom). [10] A therapeutic agent according to [1], wherein R³ and R⁴ are hydrogen atoms. [11] A therapeutic agent according to [1], wherein R⁵ is a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group or a C₆₋₁₀ aryl group (provided that R⁵ may have at least one substituent selected from the group consisting of a halogen atom and a methanesulfonyl group). [12] A therapeutic agent according to [1], wherein R⁵ is a methyl group, an ethyl group or a cyclopropyl group. [13] A therapeutic agent according to [1], wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of:

-   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-(4-fluorophenyl)urea; -   N-(2-chloro-4-((6-cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N-(4-((6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   N-(4-((6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-cyclopropyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-methoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N-(2-fluoro-4-((6-carbamoyl-7-methoxy-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N6-(2-hydroxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(1-propylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-(4-morpholino)ethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(2-fluoroethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-((2R)tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea; -   N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N′-(3-(methylsulfonyl)phenyl)urea; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-((2-fluoroethylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-ethoxyethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(4-(3-ethylureido)-3-fluoro-phenoxy)-7-methoxyquinoline-6-carboxylic     acid (2-cyanoethyl)amide; and -   N-(4-(6-(2-cyanoethyl)carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [14] A therapeutic agent according to [1], wherein the compound     represented by General Formula (I), a pharmacologically acceptable     salt thereof or a solvate thereof is at least one compound selected     from the group consisting of: -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;     and -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [15] A therapeutic agent according to [1], wherein the compound     represented by General Formula (I), a pharmacologically acceptable     salt thereof or a solvate thereof is     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [16] A therapeutic agent according to [1], wherein the compound     represented by General Formula (I), a pharmacologically acceptable     salt thereof or a solvate thereof is methanesulfonate of     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.     [17] A therapeutic agent according to any one of [1] to [1,6],     wherein the therapeutic substance for gastric cancer is at least one     selected from the group consisting of irinotecan, paclitaxel,     carboquone, nimustine, 5-fluorouracil, tegafur, UFT, doxifluridine,     carmofur, S-1, doxorubicin, mitomycin C, aclarubicin, pirarubicin,     epirubicin, docetaxel and cis-platinum.     [18] A therapeutic agent according to any one of [1] to [1,6],     wherein the therapeutic substance for gastric cancer is irinotecan,     5-fluorouracil or paclitaxel.     [19] A therapeutic agent according to any one of [1] to [16],     wherein the FGFR2 inhibitor is at least one compound selected from     the group consisting of: -   N-(3-trifluoromethyl-4-chlorophenyl)-N′-(4-(2-methylcarbamoylpyridine-4-yl)oxyphenyl)urea; -   6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridine-2-yl)ethenyl]indazole; -   5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic     acid(2-diethylaminoethyl)amide; and -   N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl)urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [20] A therapeutic agent according to [1], wherein the     undifferentiated gastric cancer comprises at least one selected from     the group consisting of a cell overexpressing FGFR2 and a cell     expressing mutant FGFR2.     [21] A therapeutic agent according to [20], wherein the mutant FGFR2     comprises a mutation site where amino acids downstream from at least     position 813 are deleted in the amino acid sequence 22-822 among the     amino acid sequence represented by SEQ ID NO:2.     [22] A therapeutic agent according to [1], wherein the     undifferentiated gastric cancer is at least one gastric cancer     selected from the group consisting of poorly differentiated     adenocarcinoma, signet-ring cell carcinoma, mucinous carcinoma and     scirrhous gastric cancer.     [23] A pharmaceutical composition for administration to a living     organism comprising at least one selected from the group consisting     of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2,     the pharmaceutical composition comprising a compound represented by     General Formula (I) below, a pharmacologically acceptable salt     thereof or a solvate thereof in combination with a therapeutic     substance for gastric cancer or a FGFR2 inhibitor:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶SO₂—, a group represented by Formula —NR⁶CO— or a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group]. [24] A pharmaceutical composition according to [23], wherein R¹ is a C₁₋₆ alkyl group (provided that R¹ may have at least one substituent selected from the group consisting of a 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, a C₁₋₆ alkoxy group, an amino group, a mono-C₁₋₆ alkylamino group and a di-C₁₋₆ alkylamino group which may have a C₁₋₆ alkyl group). [25] A pharmaceutical composition according to [23], wherein R¹ is a methyl group or a group represented by any one of the following formulae

(wherein, R^(a3) represents a methyl group; R^(a1) represents a hydrogen atom or a hydroxyl group; R^(a2) represents a methoxy group, an ethoxy group, a 1-pyrrolidinyl group, a 1-piperidinyl group, a 4-morpholinyl group, a dimethylamino group or a diethylamino group). [26] A pharmaceutical composition according to [23], wherein R¹ is a methyl group or a 2-methoxyethyl group. [27] A pharmaceutical composition according to [23], wherein R² is a cyano group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group). [28] A pharmaceutical composition according to [23], wherein R² is a cyano group or a group represented by Formula —CONHV^(a16) (wherein, V^(a16) represents a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₁₋₆ alkoxy group or a C₃₋₈ cycloalkoxy group, provided that V^(a16) may have at least one substituent selected from the group consisting of a halogen atom, a cyano group, a hydroxyl group and a C₁₋₆ alkoxy group). [29] A pharmaceutical composition according to [23], wherein R² is a group represented by Formula —CONHV^(a17) (wherein, V^(a17) represents a hydrogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group). [30] A pharmaceutical composition according to [23], wherein R² is a group represented by Formula —CONHV^(a18) (wherein, V^(a18) represents a hydrogen atom, a methyl group or a methoxy group). [31] A pharmaceutical composition according to [23], wherein Y¹ is a group represented by the following formula

(wherein, R⁷¹ represents a hydrogen atom or a halogen atom). [32] A pharmaceutical composition according to [23], wherein R³ and R⁴ are hydrogen atoms. [33] A pharmaceutical composition according to [23], wherein R⁵ is a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group or a C₆₋₁₀ aryl group (provided that R⁵ may have at least one substituent selected from the group consisting of a halogen atom and a methanesulfonyl group). [34] A pharmaceutical composition according to [23], wherein R² is a methyl group, an ethyl group or a cyclopropyl group. [35] A pharmaceutical composition according to [23], wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of:

-   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-(4-fluorophenyl)urea; -   N-(2-chloro-4-((6-cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N-(4-((6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   N-(4-((6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-cyclopropyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-methoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N-(2-fluoro-4-((6-carbamoyl-7-methoxy-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N6-(2-hydroxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(1-propylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-(4-morpholino)ethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(2-fluoroethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-((2R)tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea; -   N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N′-(3-(methylsulfonyl)phenyl)urea; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-((2-fluoroethylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-ethoxyethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(4-(3-ethylureido)-3-fluoro-phenoxy)-7-methoxyquinoline-6-carboxylic     acid (2-cyanoethyl)amide; and -   N-(4-(6-(2-cyanoethyl)carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [36] A pharmaceutical composition according to [23], wherein the     compound represented by General Formula (I), a pharmacologically     acceptable salt thereof or a solvate thereof is at least one     compound selected from the group consisting of: -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;     and -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [37] A pharmaceutical composition according to [23], wherein the     compound represented by General Formula (I), a pharmacologically     acceptable salt thereof or a solvate thereof is     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [38] A pharmaceutical composition according to [23], wherein the     compound represented by General Formula (I), a pharmacologically     acceptable salt thereof or a solvate thereof is methanesulfonate of     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.     [39] A pharmaceutical composition according to any one of [23] to     [38], wherein the therapeutic substance for gastric cancer is at     least one selected from the group consisting of irinotecan,     paclitaxel, carboquone, nimustine, 5-fluorouracil, tegafur, UFT,     doxifluridine, carmofur, S-1, doxorubicin, mitomycin C, aclarubicin,     pirarubicin, epirubicin, docetaxel and cis-platinum.     [40] A pharmaceutical composition according to any one of [23] to     [38], wherein the therapeutic substance for gastric cancer is     irinotecan, 5-fluorouracil or paclitaxel.     [41] A pharmaceutical composition according to any one of [23] to     [38], wherein the FGFR2 inhibitor is at least one compound selected     from the group consisting of: -   N-(3-trifluoromethyl-4-chlorophenyl)-N′-(4-(2-methylcarbamoylpyridine-4-yl)oxyphenyl)urea; -   6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridine-2-yl)ethenyl]indazole; -   5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic     acid(2-diethylaminoethyl)amide; and -   N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl)urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [42] A pharmaceutical composition according to [23], wherein the     mutant FGFR2 comprises a mutation site where amino acids downstream     from at least position 813 are deleted in the amino acid sequence     22-822 among the amino acid sequence represented by SEQ ID NO:2.     [43] A pharmaceutical composition according to [23], wherein the     living organism is a patient suffering from undifferentiated gastric     cancer.     [44] A pharmaceutical composition according to [43], wherein the     undifferentiated gastric cancer is at least one gastric cancer     selected from the group consisting of poorly differentiated     adenocarcinoma, signet-ring cell carcinoma, mucinous carcinoma and     scirrhous gastric cancer.     [45] A method for treating undifferentiated gastric cancer,     characterized by administering effective dosages of a compound     represented by General Formula (I) below, a pharmacologically     acceptable salt thereof or a solvate thereof and a therapeutic     substance for gastric cancer or a FGFR2 inhibitor to a living     organism:

[wherein, R⁸ represents a group represented by Formula —V¹—V²V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group]. [46] A therapeutic method according to [45], wherein R¹ is a C₁₋₆ alkyl group (provided that R¹ may have at least one substituent selected from the group consisting of a 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, a C₁₋₆ alkoxy group, an amino group, a mono-C₁₋₆ alkylamino group and a di-C₁₋₆ alkylamino group which may have a C₁₋₆ alkyl group). [47] A therapeutic method according to [45], wherein R¹ is a methyl group or a group represented by any one of the following formulae

(wherein, R^(a3) represents a methyl group; R^(a1) represents a hydrogen atom or a hydroxyl group; R^(a2) represents a methoxy group, an ethoxy group, a 1-pyrrolidinyl group, a 1-piperidinyl group, a 4-morpholinyl group, a dimethylamino group or a diethylamino group). [48] A therapeutic method according to [45], wherein R¹ is a methyl group or a 2-methoxyethyl group. [49] A therapeutic method according to [45], wherein R² is a cyano group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group). [50] A therapeutic method according to [45], wherein R² is a cyano group or a group represented by Formula —CONHV^(a16) (wherein, V^(a16) represents a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₁₋₆ alkoxy group or a C₃₋₈ cycloalkoxy group, provided that V^(a16) may have at least one substituent selected from the group consisting of a halogen atom, a cyano group, a hydroxyl group and a C₁₋₆ alkoxy group). [51] A therapeutic method according to [45], wherein R² is a group represented by Formula —CONHV^(a17) (wherein, V^(a17) represents a hydrogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group). [52] A therapeutic method according to [45], wherein R² is a group represented by Formula —CONHV^(a18) (wherein, V^(a18) represents a hydrogen atom, a methyl group or a methoxy group). [53] A therapeutic method according to [45], wherein Y¹ is a group represented by the following formula

(wherein, R⁷¹ represents a hydrogen atom or a halogen atom). [54] A therapeutic method according to [45], wherein R³ and R⁴ are hydrogen atoms. [55] A therapeutic method according to [45], wherein R⁵ is a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group or a C₆₋₁₀ aryl group (provided that R⁵ may have at least one substituent selected from the group consisting of a halogen atom and a methanesulfonyl group). [56] A therapeutic method according to [45], wherein R⁵ is a methyl group, an ethyl group or a cyclopropyl group. [57] A therapeutic method according to [45], wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of:

-   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-(4-fluorophenyl)urea; -   N-(2-chloro-4-((6-cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N-(4-((6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   N-(4-((6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-cyclopropyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-methoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N-(2-fluoro-4-((6-carbamoyl-7-methoxy-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N6-(2-hydroxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(1-propylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-(4-morpholino)ethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(2-fluoroethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-((2R)tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea; -   N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N′-(3-(methylsulfonyl)phenyl)urea; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-((2-fluoroethylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-ethoxyethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(4-(3-ethylureido)-3-fluoro-phenoxy)-7-methoxyquinoline-6-carboxylic     acid (2-cyanoethyl)amide; and -   N-(4-(6-(2-cyanoethyl)carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [58] A therapeutic method according to [45], wherein the compound     represented by General Formula (I), a pharmacologically acceptable     salt thereof or a solvate thereof is at least one compound selected     from the group consisting of: -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;     and -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [59] A therapeutic method according to [45], wherein the compound     represented by General Formula (I), a pharmacologically acceptable     salt thereof or a solvate thereof is     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [60] A therapeutic method according to [45], wherein the compound     represented by General Formula (I), a pharmacologically acceptable     salt thereof or a solvate thereof is methanesulfonate of     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.     [61] A therapeutic method according to any one of [45] to [60],     wherein the therapeutic substance for gastric cancer is at least one     selected from the group consisting of irinotecan, paclitaxel,     carboquone, nimustine, 5-fluorouracil, tegafur, UFT, doxifluridine,     carmofur, S-1, doxorubicin, mitomycin C, aclarubicin, pirarubicin,     epirubicin, docetaxel and cis-platinum.     [62] A therapeutic method according to any one of [45] to [60],     wherein the therapeutic substance for gastric cancer is irinotecan,     5-fluorouracil or paclitaxel.     [63] A therapeutic method according to any one of [45] to [60],     wherein the FGFR2 inhibitor is at least one compound selected from     the group consisting of: -   N-(3-trifluoromethyl-4-chlorophenyl)-N′-(4-(2-methylcarbamoylpyridine-4-yl)oxyphenyl)urea; -   6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridine-2-yl)ethenyl]indazole; -   5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic     acid(2-diethylaminoethyl)amide; and -   N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl)urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [64] A therapeutic method according to [45], wherein the mutant     FGFR2 comprises a mutation site where amino acids downstream from at     least position 813 are deleted in the amino acid sequence 22-822     among the amino acid sequence represented by SEQ ID NO:2.     [65] A therapeutic method according to [45], wherein the living     organism is a patient suffering from undifferentiated gastric     cancer.     [66] A therapeutic method according to [65], wherein the     undifferentiated gastric cancer is at least one gastric cancer     selected from the group consisting of poorly differentiated     adenocarcinoma, signet-ring cell carcinoma, mucinous carcinoma and     scirrhous gastric cancer.     [67] A method for treating a disease, characterized by administering     effective dosages of a compound represented by General Formula (I)     below, a pharmacologically acceptable salt thereof or a solvate     thereof and a therapeutic substance for gastric cancer or a FGFR2     inhibitor to a living organism comprising at least one selected from     the group consisting of a cell overexpressing FGFR2 and a cell     expressing mutant FGFR2:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶SO₂—, a group represented by Formula —NR⁶CO— or a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group]. [68] A therapeutic method according to [67], wherein R¹ is a C₁₋₆ alkyl group (provided that R¹ may have at least one substituent selected from the group consisting of a 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, a C₁₋₆ alkoxy group, an amino group, a mono-C₁₋₆ alkylamino group and a di-C₁₋₆ alkylamino group which may have a C₁₋₆ alkyl group). [69] A therapeutic method according to [67], wherein R¹ is a methyl group or a group represented by any one of the following formulae

(wherein, R^(a3) represents a methyl group; R^(a1) represents a hydrogen atom or a hydroxyl group; R^(a2) represents a methoxy group, an ethoxy group, a 1-pyrrolidinyl group, a 1-piperidinyl group, a 4-morpholinyl group, a dimethylamino group or a diethylamino group). [70] A therapeutic method according to [67], wherein R¹ is a methyl group or a 2-methoxyethyl group. [71] A therapeutic method according to [67], wherein R² is a cyano group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group). [72] A therapeutic method according to [67], wherein R² is a cyano group or a group represented by Formula —CONHV^(a16) (wherein, V^(a16) represents a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₁₋₆ alkoxy group or a C₃₋₈ cycloalkoxy group, provided that V^(a16) may have at least one substituent selected from the group consisting of a halogen atom, a cyano group, a hydroxyl group and a C₁₋₆ alkoxy group). [73] A therapeutic method according to [67], wherein R² is a group represented by Formula —CONHV^(a17) (wherein, V^(a17) represents a hydrogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group). [74] A therapeutic method according to [67], wherein R² is a group represented by Formula —CONHV^(a18) (wherein, V^(a18) represents a hydrogen atom, a methyl group or a methoxy group). [75] A therapeutic method according to [67], wherein Y¹ is a group represented by the following formula

(wherein, R⁷¹ represents a hydrogen atom or a halogen atom). [76] A therapeutic method according to [67], wherein R³ and R⁴ are hydrogen atoms. [77] A therapeutic method according to [67], wherein R⁵ is a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group or a C₆₋₁₀ aryl group (provided that R⁵ may have at least one substituent selected from the group consisting of a halogen atom and a methanesulfonyl group). [78] A therapeutic method according to [67], wherein R⁵ is a methyl group, an ethyl group or a cyclopropyl group. [79] A therapeutic method according to [67], wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of:

-   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-(4-fluorophenyl)urea; -   N-(2-chloro-4-((6-cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N-(4-((6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   N-(4-((6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-cyclopropyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-methoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N-(2-fluoro-4-((6-carbamoyl-7-methoxy-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N6-(2-hydroxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(1-propylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-(4-morpholino)ethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(2-fluoroethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-((2R)tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea; -   N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N′-(3-(methylsulfonyl)phenyl)urea; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-((2-fluoroethylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-ethoxyethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(4-(3-ethylureido)-3-fluoro-phenoxy)-7-methoxyquinoline-6-carboxylic     acid (2-cyanoethyl)amide; and -   N-(4-(6-(2-cyanoethyl)carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [80] A therapeutic method according to [67], wherein the compound     represented by General Formula (I), a pharmacologically acceptable     salt thereof or a solvate thereof is at least one compound selected     from the group consisting of: -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;     and -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [81] A therapeutic method according to [67], wherein the compound     represented by General Formula (I), a pharmacologically acceptable     salt thereof or a solvate thereof is     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [82] A therapeutic method according to [67], wherein the compound     represented by General Formula (I), a pharmacologically acceptable     salt thereof or a solvate thereof is methanesulfonate of     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.     [83] A therapeutic method according to any one of [67] to [82],     wherein the therapeutic substance for gastric cancer is at least one     selected from the group consisting of irinotecan, paclitaxel,     carboquone, nimustine, 5-fluorouracil, tegafur, UFT, doxifluridine,     carmofur, S-1, doxorubicin, mitomycin C, aclarubicin, pirarubicin,     epirubicin, docetaxel and cis-platinum.     [84] A therapeutic method according to any one of [67] to [82],     wherein the therapeutic substance for gastric cancer is irinotecan,     5-fluorouracil or paclitaxel.     [85] A therapeutic method according to any one of [67] to [82],     wherein the FGFR2 inhibitor is at least one compound selected from     the group consisting of: -   N-(3-trifluoromethyl-4-chlorophenyl)-N′-(4-(2-methylcarbamoylpyridine-4-yl)oxyphenyl)urea; -   6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridine-2-yl)ethenyl]     indazole; -   5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic     acid(2-diethylaminoethyl)amide; and -   N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl)urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [86] A therapeutic method according to [67], wherein the mutant     FGFR2 comprises a mutation site where amino acids downstream from at     least position 813 are deleted in the amino acid sequence 22-822     among the amino acid sequence represented by SEQ ID NO:2.     [87] A therapeutic method according to [67], wherein the living     organism is a patient suffering from undifferentiated gastric     cancer.     [88] A therapeutic method according to [87], wherein the     undifferentiated gastric cancer is at least one gastric cancer     selected from the group consisting of poorly differentiated     adenocarcinoma, signet-ring cell carcinoma, mucinous carcinoma and     scirrhous gastric cancer.     [89] Use of a compound represented by General Formula (I) below, a     pharmacologically acceptable salt thereof or a solvate thereof for     producing a therapeutic agent for undifferentiated gastric cancer in     combination with a therapeutic substance for gastric cancer or a     FGFR2 inhibitor:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group]. [90 Use according to [89], wherein R¹ is a C₁₋₆ alkyl group (provided that R¹ may have at least one substituent selected from the group consisting of a 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, a C₁₋₆ alkoxy group, an amino group, a mono-C₁₋₆ alkylamino group and a di-C₁₋₆ alkylamino group which may have a C₁₋₆ alkyl group). [91] Use according to [89], wherein R¹ is a methyl group or a group represented by any one of the following formulae

(wherein, R^(a3) represents a methyl group; R^(a1) represents a hydrogen atom or a hydroxyl group; R^(a2) represents a methoxy group, an ethoxy group, a 1-pyrrolidinyl group, a 1-piperidinyl group, a 4-morpholinyl group, a dimethylamino group or a diethylamino group). [92] Use according to [89], wherein R¹ is a methyl group or a 2-methoxyethyl group. [93] Use according to [89], wherein R² is a cyano group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group). [94] Use according to [89], wherein R² is a cyano group or a group represented by Formula —CONHV^(a16) (wherein, V^(a16) represents a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₁₋₆ alkoxy group or a C₃₋₈ cycloalkoxy group, provided that V^(a16) may have at least one substituent selected from the group consisting of a halogen atom, a cyano group, a hydroxyl group and a C₁₋₆ alkoxy group). [95] Use according to [89], wherein R² is a group represented by Formula —CONHV^(a17) (wherein, V^(a17) represents a hydrogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group). [96] Use according to [89], wherein R² is a group represented by Formula —CONHV^(a18) (wherein, V^(a18) represents a hydrogen atom, a methyl group or a methoxy group). [97] Use according to [89], wherein Y¹ is a group represented by the following formula

(wherein, R⁷¹ represents a hydrogen atom or a halogen atom). [98] Use according to [89], wherein R³ and R⁴ are hydrogen atoms. [99] Use according to [89], wherein R⁵ is a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group or a C₆₋₁₀ aryl group (provided that R⁵ may have at least one substituent selected from the group consisting of a halogen atom and a methanesulfonyl group). [100] Use according to [89], wherein R⁵ is a methyl group, an ethyl group or a cyclopropyl group. [101] Use according to [89], wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of:

-   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-(4-fluorophenyl)urea; -   N-(2-chloro-4-((6-cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N-(4-((6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   N-(4-((6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-cyclopropyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-methoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N-(2-fluoro-4-((6-carbamoyl-7-methoxy-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N6-(2-hydroxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(1-propylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-(4-morpholino)ethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(2-fluoroethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-((2R)tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea; -   N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N′-(3-(methylsulfonyl)phenyl)urea; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-((2-fluoroethylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-ethoxyethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(4-(3-ethylureido)-3-fluoro-phenoxy)-7-methoxyquinoline-6-carboxylic     acid (2-cyanoethyl)amide; and -   N-(4-(6-(2-cyanoethyl)carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [102] Use according to [89], wherein the compound represented by     General Formula (I), a pharmacologically acceptable salt thereof or     a solvate thereof is at least one compound selected from the group     consisting of: -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;     and -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [103] Use according to [89], wherein the compound represented by     General Formula (I), a pharmacologically acceptable salt thereof or     a solvate thereof is     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [104] Use according to [89], wherein the compound represented by     General Formula (I), a pharmacologically acceptable salt thereof or     a solvate thereof is methanesulfonate of     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.     [105] Use according to any one of [89] to [104], wherein the     therapeutic substance for gastric cancer is at least one selected     from the group consisting of irinotecan, paclitaxel, carboquone,     nimustine, 5-fluorouracil, tegafur, UFT, doxifluridine, carmofur,     S-1, doxorubicin, mitomycin C, aclarubicin, pirarubicin, epirubicin,     docetaxel and cis-platinum.     [106] Use according to any one of [89] to [104], wherein the     therapeutic substance for gastric cancer is irinotecan,     5-fluorouracil or paclitaxel.     [107] Use according to any one of [89] to [104], wherein the FGFR2     inhibitor is at least one compound selected from the group     consisting of: -   N-(3-trifluoromethyl-4-chlorophenyl)-N′-(4-(2-methylcarbamoylpyridine-4-yl)oxyphenyl)urea; -   6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridine-2-yl)ethenyl]indazole; -   5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic     acid(2-diethylaminoethyl)amide; and -   N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl)urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [108] Use according to [89], wherein the undifferentiated gastric     cancer comprises at least one selected from the group consisting of     a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.     [109] Use according to [108], wherein the mutant FGFR2 comprises a     mutation site where amino acids downstream from at least position     813 are deleted in the amino acid sequence 22-822 among the amino     acid sequence represented by SEQ ID NO:2.     [110] Use according to [89], wherein the undifferentiated gastric     cancer is at least one gastric cancer selected from the group     consisting of poorly differentiated adenocarcinoma, signet-ring cell     carcinoma, mucinous carcinoma and scirrhous gastric cancer.     [111] Use of a compound represented by General Formula (I) below, a     pharmacologically acceptable salt thereof or a solvate thereof for     producing a pharmaceutical composition in combination with a     therapeutic substance for gastric cancer or a FGFR2 inhibitor for     administration to a living organism comprising at least one selected     from the group consisting of a cell overexpressing FGFR2 and a cell     expressing mutant FGFR2:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶, a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group]. [112] Use according to [111], wherein R¹ is a C₁₋₆ alkyl group (provided that R¹ may have at least one substituent selected from the group consisting of a 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, a C₁₋₆ alkoxy group, an amino group, a mono-C₁₋₆ alkylamino group and a di-C₁₋₆ alkylamino group which may have a C₁₋₆ alkyl group). [113] Use according to [111], wherein R¹ is a methyl group or a group represented by any one of the following formulae

(wherein, R^(a3) represents a methyl group; R^(a1) represents a hydrogen atom or a hydroxyl group; R^(a2) represents a methoxy group, an ethoxy group, a 1-pyrrolidinyl group, a 1-piperidinyl group, a 4-morpholinyl group, a dimethylamino group or a diethylamino group). [114] Use according to [111], wherein R¹ is a methyl group or a 2-methoxyethyl group. [115] Use according to [111], wherein R² is a cyano group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group). [116] Use according to [111], wherein R² is a cyano group or a group represented by Formula —CONHV^(a16) (wherein, V^(a16) represents a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₁₋₆ alkoxy group or a C₃₋₈ cycloalkoxy group, provided that V^(a16) may have at least one substituent selected from the group consisting of a halogen atom, a cyano group, a hydroxyl group and a C₁₋₆ alkoxy group). [117] Use according to [111], wherein R² is a group represented by Formula —CONHV^(a17) (wherein, V^(a17) represents a hydrogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group). [118] Use according to [111], wherein R² is a group represented by Formula —CONHV^(a18) (wherein, V^(a18) represents a hydrogen atom, a methyl group or a methoxy group). [119] Use according to [111], wherein Y¹ is a group represented by the following formula

(wherein, R⁷¹ represents a hydrogen atom or a halogen atom). [120] Use according to [111], wherein R³ and R⁴ are hydrogen atoms. [121] Use according to [111], wherein R⁵ is a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group or a C₆₋₁₀ aryl group (provided that R⁵ may have at least one substituent selected from the group consisting of a halogen atom and a methanesulfonyl group). [122] Use according to [111], wherein R⁵ is a methyl group, an ethyl group or a cyclopropyl group. [123] Use according to [111], wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of:

-   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-(4-fluorophenyl)urea; -   N-(2-chloro-4-((6-cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N-(4-((6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   N-(4-((6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-cyclopropyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-methoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N-(2-fluoro-4-((6-carbamoyl-7-methoxy-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N6-(2-hydroxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(1-propylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-(4-morpholino)ethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(2-fluoroethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-((2R)tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea; -   N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N′-(3-(methylsulfonyl)phenyl)urea; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-((2-fluoroethylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-ethoxyethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(4-(3-ethylureido)-3-fluoro-phenoxy)-7-methoxyquinoline-6-carboxylic     acid (2-cyanoethyl)amide; and -   N-(4-(6-(2-cyanoethyl)carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [124] Use according to [111], wherein the compound represented by     General Formula (I), a pharmacologically acceptable salt thereof or     a solvate thereof is at least one compound selected from the group     consisting of: -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;     and -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [125] Use according to [111], wherein the compound represented by     General Formula (I), a pharmacologically acceptable salt thereof or     a solvate thereof is     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [126] Use according to [111], wherein the compound represented by     General Formula (I), a pharmacologically acceptable salt thereof or     a solvate thereof is methanesulfonate of     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.     [127] Use according to any one of [111] to [116], wherein the     therapeutic substance for gastric cancer is at least one selected     from the group consisting of irinotecan, paclitaxel, carboquone,     nimustine, 5-fluorouracil, tegafur, UFT, doxifluridine, carmofur,     S-1, doxorubicin, mitomycin C, aclarubicin, pirarubicin, epirubicin,     docetaxel and cis-platinum.     [128] Use according to any one of [111] to [116], wherein the     therapeutic substance for gastric cancer is irinotecan,     5-fluorouracil or paclitaxel.     [129] Use according to any one of [111] to [116], wherein the FGFR2     inhibitor is at least one compound selected from the group     consisting of: -   N-(3-trifluoromethyl-4-chlorophenyl)-N′-(4-(2-methylcarbamoylpyridine-4-yl)oxyphenyl)urea; -   6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridine-2-yl)ethenyl]indazole; -   5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic     acid(2-diethylaminoethyl)amide; and -   N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl)urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [130] Use according to [111], wherein the undifferentiated gastric     cancer comprises at least one selected from the group consisting of     a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.     [131] Use according to [130], wherein the mutant FGFR2 comprises a     mutation site where amino acids downstream from at least position     813 are deleted in the amino acid sequence 22-822 among the amino     acid sequence represented by SEQ ID NO:2.     [132] Use according to [111], wherein the undifferentiated gastric     cancer is at least one gastric cancer selected from the group     consisting of poorly differentiated adenocarcinoma, signet-ring cell     carcinoma, mucinous carcinoma and scirrhous gastric cancer.     [133] A compound represented by General Formula (I) below, a     pharmacologically acceptable salt thereof or a solvate thereof for     treating undifferentiated gastric cancer in combination with a     therapeutic substance for gastric cancer or a FGFR2 inhibitor:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group);

Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group]. [134] A compound according to [133], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R¹ is a C₁₋₆ alkyl group (provided that R¹ may have at least one substituent selected from the group consisting of a 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, a C₁₋₆ alkoxy group, an amino group, a mono-C₁₋₆ alkylamino group and a di-C₁₋₆ alkylamino group which may have a C₁₋₆ alkyl group). [135] A compound according to [133], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R¹ is a methyl group or a group represented by any one of the following formulae

(wherein, R^(a3) represents a methyl group; R^(a1) represents a hydrogen atom or a hydroxyl group; R^(a2) represents a methoxy group, an ethoxy group, a 1-pyrrolidinyl group, a 1-piperidinyl group, a 4-morpholinyl group, a dimethylamino group or a diethylamino group). [136] A compound according to [133], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R¹ is a methyl group or a 2-methoxyethyl group. [137] A compound according to [133], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R² is a cyano group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group). [138] A compound according to [133], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R² is a cyano group or a group represented by Formula —CONHV^(a16) (wherein, V^(a16) represents a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₁₋₆ alkoxy group or a C₃₋₈ cycloalkoxy group, provided that V^(a16) may have at least one substituent selected from the group consisting of a halogen atom, a cyano group, a hydroxyl group and a C₁₋₆ alkoxy group). [139] A compound according to [133], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R² is a group represented by Formula —CONHV^(a17) (wherein, V^(a17) represents a hydrogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group). [140] A compound according to [133], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R² is a group represented by Formula —CONHV^(a11) (wherein, V^(a11) represents a hydrogen atom, a methyl group or a methoxy group). [141] A compound according to [133], a pharmacologically acceptable salt thereof or a solvate thereof, wherein Y¹ is a group represented by the following formula

(wherein, R⁷¹ represents a hydrogen atom or a halogen atom). [142] A compound according to [133], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R³ and R⁴ are hydrogen atoms. [143] A compound according to [133], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R⁵ is a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group or a C₆₋₁₀ aryl group (provided that R⁵ may have at least one substituent selected from the group consisting of a halogen atom and a methanesulfonyl group). [144] A compound according to [133], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R⁵ is a methyl group, an ethyl group or a cyclopropyl group. [145] A compound according to [133], a pharmacologically acceptable salt thereof or a solvate thereof, wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of:

-   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-(4-fluorophenyl)urea; -   N-(2-chloro-4-((6-cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N-(4-((6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   N-(4-((6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-cyclopropyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-methoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N-(2-fluoro-4-((6-carbamoyl-7-methoxy-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N6-(2-hydroxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(1-propylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-(4-morpholino)ethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(2-fluoroethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-((2R)tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea; -   N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N′-(3-(methylsulfonyl)phenyl)urea; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-((2-fluoroethylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-ethoxyethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(4-(3-ethylureido)-3-fluoro-phenoxy)-7-methoxyquinoline-6-carboxylic     acid (2-cyanoethyl)amide; and -   N-(4-(6-(2-cyanoethyl)carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [146] A compound according to [133], a pharmacologically acceptable     salt thereof or a solvate thereof, wherein the compound represented     by General Formula (I), a pharmacologically acceptable salt thereof     or a solvate thereof is at least one compound selected from the     group consisting of: -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;     and -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [147] A compound according to [133], a pharmacologically acceptable     salt thereof or a solvate thereof, wherein the compound represented     by General Formula (I), a pharmacologically acceptable salt thereof     or a solvate thereof is     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [148] A compound according to [133], a pharmacologically acceptable     salt thereof or a solvate thereof, wherein the compound represented     by General Formula (I), a pharmacologically acceptable salt thereof     or a solvate thereof is methanesulfonate of     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.     [149] A compound according to any one of [133] to [148], a     pharmacologically acceptable salt thereof or a solvate thereof,     wherein the therapeutic substance for gastric cancer is at least one     selected from the group consisting of irinotecan, paclitaxel,     carboquone, nimustine, 5-fluorouracil, tegafur, UFT, doxifluridine,     carmofur, S-1, doxorubicin, mitomycin C, aclarubicin, pirarubicin,     epirubicin, docetaxel and cis-platinum.     [150] A compound according to any one of [133] to [148], a     pharmacologically acceptable salt thereof or a solvate thereof,     wherein the therapeutic substance for gastric cancer is irinotecan,     5-fluorouracil or paclitaxel.     [151] A compound according to any one of [133] to [148], a     pharmacologically acceptable salt thereof or a solvate thereof,     wherein the FGFR2 inhibitor is at least one compound selected from     the group consisting of: -   N-(3-trifluoromethyl-4-chlorophenyl)-N′-(4-(2-methylcarbamoylpyridine-4-yl)oxyphenyl)urea; -   6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridine-2-yl)ethenyl]indazole; -   5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic     acid(2-diethylaminoethyl)amide; and -   N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl)urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [152] A compound according to [133], a pharmacologically acceptable     salt thereof or a solvate thereof, wherein the undifferentiated     gastric cancer comprises at least one selected from the group     consisting of a cell overexpressing FGFR2 and a cell expressing     mutant FGFR2.     [153] A compound according to [152], a pharmacologically acceptable     salt thereof or a solvate thereof, wherein the mutant FGFR2     comprises a mutation site where amino acids downstream from at least     position 813 are deleted in the amino acid sequence 22-822 among the     amino acid sequence represented by SEQ ID NO:2.     [154] A compound according to [133], a pharmacologically acceptable     salt thereof or a solvate thereof, wherein the undifferentiated     gastric cancer is at least one gastric cancer selected from the     group consisting of poorly differentiated adenocarcinoma,     signet-ring cell carcinoma, mucinous carcinoma and scirrhous gastric     cancer.     [155] A compound represented by General Formula (I) below, a     pharmacologically acceptable salt thereof or a solvate thereof for     administration in combination with a therapeutic substance for     gastric cancer or a FGFR2 inhibitor to a living organism comprising     at least one selected from the group consisting of a cell     overexpressing FGFR2 and a cell expressing mutant FGFR2:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group]. [156] A compound according to [155], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R¹ is a C₁₋₆ alkyl group (provided that R¹ may have at least one substituent selected from the group consisting of a 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, a C₁₋₆ alkoxy group, an amino group, a mono-C₁₋₆ alkylamino group and a di-C₁₋₆ alkylamino group which may have a C₁₋₆ alkyl group). [157] A compound according to [155], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R¹ is a methyl group or a group represented by any one of the following formulae

(wherein, R^(a3) represents a methyl group; R^(a1) represents a hydrogen atom or a hydroxyl group; R^(a2) represents a methoxy group, an ethoxy group, a 1-pyrrolidinyl group, a 1-piperidinyl group, a 4-morpholinyl group, a dimethylamino group or a diethylamino group). [158] A compound according to [155], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R¹ is a methyl group or a 2-methoxyethyl group. [159] A compound according to [155], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R² is a cyano group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group). [160] A compound according to [155], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R² is a cyano group or a group represented by Formula —CONHV^(a16) (wherein, V^(a16) represents a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₁₋₆ alkoxy group or a C₃₋₈ cycloalkoxy group, provided that V^(a16) may have at least one substituent selected from the group consisting of a halogen atom, a cyano group, a hydroxyl group and a C₁₋₆ alkoxy group). [161] A compound according to [155], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R² is a group represented by Formula —CONHV^(a17) (wherein, V^(a11) represents a hydrogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group). [162] A compound according to [155], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R² is a group represented by Formula —CONHV^(a11) (wherein, V^(a11) represents a hydrogen atom, a methyl group or a methoxy group). [163] A compound according to [155], a pharmacologically acceptable salt thereof or a solvate thereof, wherein Y¹ is a group represented by the following formula

(wherein, R⁷¹ represents a hydrogen atom or a halogen atom). [164] A compound according to [155], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R³ and R⁴ are hydrogen atoms. [165] A compound according to [155], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R⁵ is a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group or a C₆₋₁₀ aryl group (provided that R⁵ may have at least one substituent selected from the group consisting of a halogen atom and a methanesulfonyl group). [166] A compound according to [155], a pharmacologically acceptable salt thereof or a solvate thereof, wherein R⁵ is a methyl group, an ethyl group or a cyclopropyl group. [167] A compound according to [155], a pharmacologically acceptable salt thereof or a solvate thereof, wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of:

-   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-(4-fluorophenyl)urea; -   N-(2-chloro-4-((6-cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N-(4-((6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   N-(4-((6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-cyclopropyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-methoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N-(2-fluoro-4-((6-carbamoyl-7-methoxy-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N6-(2-hydroxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(1-propylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-(4-morpholino)ethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(2-fluoroethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-((2R)tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea; -   N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N′-(3-(methylsulfonyl)phenyl)urea; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-((2-fluoroethylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-ethoxyethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(4-(3-ethylureido)-3-fluoro-phenoxy)-7-methoxyquinoline-6-carboxylic     acid (2-cyanoethyl)amide; and -   N-(4-(6-(2-cyanoethyl)carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [168] A compound according to [155], a pharmacologically acceptable     salt thereof or a solvate thereof, wherein the compound represented     by General Formula (I), a pharmacologically acceptable salt thereof     or a solvate thereof is at least one compound selected from the     group consisting of: -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;     and -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [169] A compound according to [155], a pharmacologically acceptable     salt thereof or a solvate thereof, wherein the compound represented     by General Formula (I), a pharmacologically acceptable salt thereof     or a solvate thereof is     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide,     a pharmacologically acceptable salt thereof or a solvate thereof.     [170] A compound according to [155], a pharmacologically acceptable     salt thereof or a solvate thereof, wherein the compound represented     by General Formula (I), a pharmacologically acceptable salt thereof     or a solvate thereof is methanesulfonate of     4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.     [171] A compound according to any one of [155] to [170], a     pharmacologically acceptable salt thereof or a solvate thereof,     wherein the therapeutic substance for gastric cancer is at least one     selected from the group consisting of irinotecan, paclitaxel,     carboquone, nimustine, 5-fluorouracil, tegafur, UFT, doxifluridine,     carmofur, S-1, doxorubicin, mitomycin C, aclarubicin, pirarubicin,     epirubicin, docetaxel and cis-platinum.     [172] A compound according to any one of [155] to [170], a     pharmacologically acceptable salt thereof or a solvate thereof,     wherein the therapeutic substance for gastric cancer is irinotecan,     5-fluorouracil or paclitaxel.     [173] A compound according to any one of [155] to [170], a     pharmacologically acceptable salt thereof or a solvate thereof,     wherein the FGFR2 inhibitor is at least one compound selected from     the group consisting of: -   N-(3-trifluoromethyl-4-chlorophenyl)-N′-(4-(2-methylcarbamoylpyridine-4-yl)oxyphenyl)urea; -   6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridine-2-yl)ethenyl]indazole; -   5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic     acid(2-diethylaminoethyl)amide; and -   N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl)urea,     a pharmacologically acceptable salt thereof or a solvate thereof.     [174] A compound according to [155], a pharmacologically acceptable     salt thereof or a solvate thereof, wherein the undifferentiated     gastric cancer comprises at least one selected from the group     consisting of a cell overexpressing FGFR2 and a cell expressing     mutant FGFR2.     [175] A compound according to [174], a pharmacologically acceptable     salt thereof or a solvate thereof, wherein the mutant FGFR2     comprises a mutation site where amino acids downstream from at least     position 813 are deleted in the amino acid sequence 22-822 among the     amino acid sequence represented by SEQ ID NO:2.     [176] A compound according to [155], a pharmacologically acceptable     salt thereof or a solvate thereof, wherein the undifferentiated     gastric cancer is at least one gastric cancer selected from the     group consisting of poorly differentiated adenocarcinoma,     signet-ring cell carcinoma, mucinous carcinoma and scirrhous gastric     cancer.     [177] A kit comprising:

(a) at least one selected from the group consisting of a packaging container, an instruction and a package insert describing use of a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor; and

(b) a therapeutic agent for undifferentiated gastric cancer comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group]. [178] A kit comprising:

(a) at least one selected from the group consisting of a packaging container, an instruction and a package insert describing use of a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor; and

(b) a pharmaceutical composition comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group]. [179] A kit characterized by a set of a therapeutic agent for undifferentiated gastric cancer comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof and a formulation comprising a therapeutic substance for gastric cancer or a FGFR2 inhibitor:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group]. [180] A kit used for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, the kit characterized by a set of a formulation comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof and a formulation comprising a therapeutic substance for gastric cancer or a FGFR2 inhibitor:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group]. [181] A therapeutic agent for undifferentiated gastric cancer comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof characterized by administration to a living organism with a therapeutic substance for gastric cancer or a FGFR2 inhibitor:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group]. [182] A pharmaceutical composition for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, the pharmaceutical composition comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof characterized by administration to the living organism with a therapeutic substance for gastric cancer or a FGFR2 inhibitor:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group].

According to (1) to (42) and [1] to [182] above, a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is as follows. A compound represented by:

[wherein, R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group); R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group); Y¹ represents a group represented by either one of the following formulae

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom); R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group; and R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group], a pharmacologically acceptable salt thereof or a solvate thereof.

Furthermore, according to (1) to (42) above, the therapeutic substance for gastric cancer may be at least one selected from the group consisting of irinotecan, paclitaxel, carboquone, nimustine, 5-fluorouracil, tegafur, UFT, doxifluridine, carmofur, S-1, doxorubicin (Adriamycin), mitomycin C, aclarubicin, pirarubicin, epirubicin, docetaxel and cis-platinum (Cisplastin). A preferable therapeutic substance for gastric cancer is irinotecan, 5-fluorouracil or paclitaxel.

Moreover, according to (1) to (42) above, the FGFR2 inhibitor may comprise, for example, a compound that is not comprised in compounds represented by General Formula (I), and may include at least one compound selected from the group consisting of:

-   N-(3-trifluoromethyl-4-chlorophenyl)-N′-(4-(2-methylcarbamoylpyridine-4-yl)oxyphenyl)urea     (BAY 43-9006); -   6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridine-2-yl)ethenyl]indazole     (AG013736); -   5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic     acid(2-diethylaminoethyl)amide (SU11248); and -   N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl)urea     (KRN951),     a pharmacologically acceptable salt thereof or a solvate thereof.

The present invention provides a therapeutic agent, a kit and a therapeutic method for undifferentiated gastric cancer that show an excellent anti-tumor activity, use of a FGFR2 inhibitor for producing the therapeutic agent and a FGFR2 inhibitor for the therapeutic agent.

More specifically, there is provided a therapeutic agent, a kit and a therapeutic method for undifferentiated gastric cancer that show an excellent anti-tumor activity and that can be used for treating undifferentiated gastric cancer by combining:

(i) a FGFR2 inhibitor such as a compound represented by General Formula (I) and a therapeutic substance for gastric cancer;

(ii) a FGFR2 inhibitor such as a compound represented by General Formula (I) and a FGFR2 inhibitor that is not comprised in the compounds represented by General Formula (I); or

(iii) a FGFR2 inhibitor such as a FGFR2 inhibitor that is not comprised in the compounds represented by General Formula (I) and a therapeutic substance for gastric cancer.

The present invention also provides a pharmaceutical composition and a kit for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, a method for treating a disease of the living organism, use of a FGFR2 inhibitor for producing the pharmaceutical composition and a FGFR2 inhibitor for the pharmaceutical composition.

More specifically, there is provided a pharmaceutical composition, a kit and a therapeutic method for the living organism, which show an excellent anti-tumor activity and that can be used for treating a disease by combining:

(i) a FGFR2 inhibitor such as a compound represented by General Formula (I) and a therapeutic substance for gastric cancer;

(ii) a FGFR2 inhibitor such as a compound represented by General Formula (I) and a FGFR2 inhibitor that is not comprised in the compounds represented by General Formula (I); or

(iii) a FGFR2 inhibitor such as a FGFR2 inhibitor that is not comprised in the compounds represented by General Formula (I) and a therapeutic substance for gastric cancer.

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 shows the effect of combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A) (3 mg/kg) and irinotecan hydrochloride (100 mg/kg) on suppression of tumor growth in subcutaneous transplanted (xenograft) models (in vivo) of human scirrhous gastric cancer cell line (HSC-39).

FIG. 2 shows the effect of combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A) (10 mg/kg) and irinotecan hydrochloride (100 mg/kg) on suppression of tumor growth in subcutaneous transplanted (xenograft) models (in vivo) of human scirrhous gastric cancer cell line (HSC-39).

FIG. 3 shows the effect of combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A) (30 mg/kg) and irinotecan hydrochloride (100 mg/kg) on suppression of tumor growth in subcutaneous transplanted (xenograft) models (in vivo) of human scirrhous gastric cancer cell line (HSC-39).

FIG. 4 shows the effect of combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A) (3 mg/kg) and 5-fluorouracil (50 mg/kg) on suppression of tumor growth in subcutaneous transplanted (xenograft) models (in vivo) of human scirrhous gastric cancer cell line (HSC-39).

FIG. 5 shows the effect of combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A) (10 mg/kg) and 5-fluorouracil (50 mg/kg) on suppression of tumor growth in subcutaneous transplanted (xenograft) models (in vivo) of human scirrhous gastric cancer cell line (HSC-39).

FIG. 6 shows the effect of combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A) (30 mg/kg) and 5-fluorouracil (50 mg/kg) on suppression of tumor growth in subcutaneous transplanted (xenograft) models (in vivo) of human scirrhous gastric cancer cell line (HSC-39).

FIG. 7 shows the effect of combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A) (3 mg/kg) and paclitaxel (14 mg/kg) on suppression of tumor growth in subcutaneous transplanted (xenograft) models (in vivo) of human scirrhous gastric cancer cell line (HSC-39).

FIG. 8 shows the effect of combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A) (10 mg/kg) and paclitaxel (14 mg/kg) on suppression of tumor growth in subcutaneous transplanted (xenograft) models (in vivo) of human scirrhous gastric cancer cell line (HSC-39).

FIG. 9 shows the effect of combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A) (30 mg/kg) and paclitaxel (14 mg/kg) on suppression of tumor growth in subcutaneous transplanted (xenograft) models (in vivo) of human scirrhous gastric cancer cell line (HSC-39).

BEST MODES FOR CARRYING OUT THE INVENTION

Hereinafter, embodiments of the present invention will be described. The following embodiments are examples provided for illustrating the present invention, and the present invention is not intended to be limited thereto. The present invention may be carried out in various embodiments without departing from the spirit of the invention.

The publications, laid-open patent publications, patent publications and other patent documents cited herein are incorporated herein by reference. The present specification incorporates the disclosure of U.S. provisional application No. 60/887,006 (filed on 29 Jan., 2007) based on which the present application claims priority.

1. FGFR2 Inhibitor

(1) FGFR2

According to the present invention, FGFR2 comprises a polypeptide including an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO:2 (GenBank Accession No:NM_(—)022970) or to the amino acids 22-822 of the amino acid sequence represented by SEQ ID NO:2. The polypeptide including the amino acid sequence represented by SEQ ID NO:2 is coded, for example, by a polynucleotide including the base sequence represented by SEQ ID NO:1. Usually, processing of the polypeptide comprising the amino acid sequence represented by SEQ ID NO:2 yields a mature form.

Examples of a polypeptide having an amino acid sequence substantially identical to the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2 include those selected from the group consisting of (a) to (d) below:

(a) a polypeptide comprising the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2;

(b) a polypeptide comprising an amino acid sequence having one or more (e.g., one or a few) amino acids deleted, substituted or added, or mutated by a combination thereof in the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2, and having substantially the same activity as FGFR2;

(c) a polypeptide encoded by a polynucleotide that hybridizes with a polynucleotide having a base sequence complementary to the base sequence represented by SEQ ID NO: 1 under stringent conditions, and having substantially the same activity as FGFR2; and

(d) a polypeptide having an amino acid sequence having 90% or higher, preferably about 95% or higher and more preferably about 98% or higher identity (also referred to as “homology”) to the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2, and having substantially the same activity as FGFR2.

Herein, the phrase “having substantially the same activity as FGFR2” means that at least one of the intracellular signals caused by ligand (e.g., FGF) binding is identical to one of the signals of a protein having the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2, and that the activation level of the intracellular signal is comparable to that of the protein having the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2. Furthermore, the term “comparable” means, for example, that the activation level of the intracellular signal caused by ligand (e.g., FGF) binding is at least 10%, preferably at least 30% of the activation level of the intracellular signal of a protein having the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2, which can be referred to as substantially the same activity. Examples of intracellular signals caused by ligand binding include: FGFR2 phosphorylation; Raf, MEK, ERK1 and ERK2 phosphorylation owing to FGFR2 phosphorylation; phosphorylation of phosphatidylinositol 3 kinase; Akt phosphorylation; phosphorylation of phospholipase-C-γ; increase in inositol 1,4,5-trisphosphate (IP3); and increase in diacylglycerol (DAG).

The activity of an intracellular signal caused by ligand binding can be measured by a conventional method such as immunoprecipitation method and western blotting.

Examples of amino acid sequences having one or more (e.g., one or a few) amino acids deleted, substituted or added, or mutated by a combination thereof in the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2 include:

(i) an amino acid sequence having 1-9 (e.g., 1-5, preferably 1-3, more preferably 1-2 and still more preferably one) amino acids deleted from the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2;

(ii) an amino acid sequence having 1-9 (e.g., 1-5, preferably 1-3, more preferably 1-2 and still more preferably one) amino acids added to the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2;

(iii) an amino acid sequence having 1-9 (e.g., 1-5, preferably 1-3, more preferably 1-2 and still more preferably one) amino acids substituted with other amino acids in the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2; and

(iv) an amino acid sequence mutated by a combination of (i) to (iii) above.

As used herein, “deletion” of an amino acid refers to a mutation where one or more amino acid residues in the sequence are deleted, including deletion of amino acid residues from the end of the amino acid sequence and deletion in the middle of the amino acid sequence.

As used herein, “addition” of an amino acid refers to a mutation where one or more amino acid residues are added to the sequence, including addition of amino acid residues to the end of the amino acid sequence and addition in the middle of the amino acid sequence. Addition in the middle of the sequence may also be referred to as “insertion”.

As used herein, “substitution” of an amino acid refers to a mutation where one or more amino acid residues in the sequence are substituted with different types of amino acid residues. When the amino acid sequence of FGFR2 is modified by such substitution, conservative substitution is preferable in order to retain the function of a protein. Conservative substitution means to alter a sequence to code an amino acid having similar property to the original amino acid. The property of amino acids can be classified, for example, into nonpolar amino acids (Ala, Ile, Leu, Met, Phe, Pro, Trp, Val), uncharged amino acids (Asn, Cys, Gln, Gly, Ser, Thr, Tyr), acidic amino acids (Asp, Glu), basic amino acids (Arg, His, Lys), neutral amino acids (Ala, Asn, Cys, Gln, Gly, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val), aliphatic amino acids (Ala, Gly), branched amino acids (Ile, Leu, Val), hydroxyamino acids (Ser, Thr), amide amino acids (Gln, Asn), sulfur-containing amino acids (Cys, Met), aromatic amino acids (His, Phe, Trp, Tyr), heterocyclic amino acids (His, Trp), imino acids (Pro, 4Hyp) and the like.

Thus, substitution, for example, between nonpolar amino acids or between uncharged amino acids, is preferable, among which, substitutions between Ala, Val, Leu and Ile, between Ser and Thr, between Asp and Glu, between Asn and Gln, between Lys and Arg, and between Phe and Tyr are favorable as substitution that retains the property of the protein. There is no limitation as to the number and the site of the amino acid to be mutated.

An example of a polypeptide having substantially the same amino acid sequence as the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2 includes a polypeptide encoded by a polynucleotide that hybridizes with a polynucleotide having a base sequence complementary to the base sequence represented by SEQ ID NO:1 under stringent conditions, and having substantially the same activity as FGFR2 as described above.

Herein, specific examples of polynucleotides that hybridize under stringent conditions include polynucleotides including base sequences having at least 90% or higher, preferably 95% or higher, more preferably 97% or higher, more preferably 98% or higher, or still more preferably 99% or higher identity with the base sequence represented by SEQ ID NO:1 when calculated using homology search software such as FASTA, BLAST, Smith-Waterman [Meth. Enzym., 164, 765 (1988)] with default (initial setting) parameters. Examples of such stringent conditions include “2×SSC, 0.1% SDS, 50° C.”, “2×SSC, 0.1% SDS, 42° C.,” and “1×SSC, 0.1% SDS, 37° C.”, and for higher stringent conditions “2×SSC, 0.1% SDS, 65° C.,” “0.5×SSC, 0.1% SDS, 42° C.,” and “0.2×SSC, 0.1% SDS, 65° C.”.

Hybridization can be carried out according to a known method. When a commercially available library is used, hybridization may be carried out according to the method described in the attached instruction.

Examples of polynucleotides that hybridize with a polynucleotide having a base sequence complementary to the base sequence represented by SEQ ID NO:1 under stringent conditions include polynucleotides comprising a base sequence having 90% or higher, preferably 95% or higher and more preferably 98% or higher identity with the base sequence represented by SEQ ID NO:1.

Examples of polynucleotides that hybridize with a polynucleotide having a base sequence complementary to the base sequence represented by SEQ ID NO:1 under stringent conditions include base sequences having one or more (e.g., one or several) nucleic acids mutated, for example, deleted, substituted or added in the base sequence represented by SEQ ID NO:1.

Examples of polynucleotides that hybridize with a polynucleotide having a base sequence complementary to the base sequence represented by SEQ ID NO:1 under stringent conditions include:

(i) a base sequence having 1-9 (e.g., 1-5, preferably 1-3, more preferably 1-2 and still more preferably one) nucleic acids deleted from the base sequence represented by SEQ ID NO:1;

(ii) a base sequence having 1-9 (e.g., 1-5, preferably 1-3, more preferably 1-2 and still more preferably one) nucleic acids added to the base sequence represented by SEQ ID NO:1;

(iii) a base sequence having 1-9 (e.g., 1-5, preferably 1-3, more preferably 1-2 and still more preferably one) nucleic acids substituted with other nucleic acids in the base sequence represented by SEQ ID NO:1; and

(iv) a base sequence mutated by a combination of (i) to (iii) above.

Herein, the term “identity” (also referred to as “homology”) of an amino acid sequence is used to indicate the degree of consistency of amino acid residues between the sequences to be compared. In order to calculate identity of a given amino acid sequence to an amino acid sequence to be compared, the presence of gaps and the property of the amino acids are considered (Wilbur, Natl. Acad. Sci. U.S.A. 80:726-730 (1983)). For the calculation of identity, a commercially available software BLAST (Altschul: J. Mol. Biol. 215:403-410 (1990)), FASTA (Peasron: Methods in Enzymology 183:63-69 (1990)) or the like can be used.

The “identity” value may be any value as long as it is obtained by using a homology search program known to those skilled in the art. For example, for such calculation, the default (initial setting) parameters can be used in homology algorithm BLAST (Basic local alignment search tool) http://www.ncbi.nlm.nih.gov/BLAST/ of the National Center for Biotechnology Information (NCBI).

According to the present invention, FGFR2 comprises mutant FGFR2 described below.

(2) Cell Overexpressing FGFR2

According to the present invention, a cell overexpressing FGFR2 comprises, for example, a cell expressing FGFR2 for a significant amount as compared to a normal cell. In addition, according to the present invention, a cell overexpressing FGFR2 comprises, for example, a cell expressing FGFR2 for at least 1.5 times higher, preferably at least 2 times higher, more preferably at least 3 times higher, still more preferably at least 4 times higher than a normal cell. Herein, according to the invention, a “normal cell” refers to, for example, cells other than cancer (e.g., undifferentiated gastric cancer) cells.

According to the present invention, a cell overexpressing FGFR2 is preferably undifferentiated gastric cancer cell, more preferably at least one cell selected from the group consisting of poorly differentiated adenocarcinoma, signet-ring cell carcinoma, mucinous carcinoma and scirrhous gastric cancer.

An expression level of FGFR2 may be analyzed, for example, by measuring the protein and/or the mRNA of FGFR2 expressed in the cell.

Protein can be measured, for example, by an immunochemical method (e.g., immunohistochemistry method, immunoprecipitation, western blotting, flow cytometry, ELISA, RIA, etc.), mass spectrometry or the like, preferably an immunochemical method, particularly preferably flow cytometry. These methods may be carried out according to conventional techniques.

On the other hand, mRNA can be measured, for example, by a method such as in situ hybridization, northern blot analysis, DNA microarray, RT-PCR, quantitative RT-PCR or the like, preferably RT-PCR or quantitative RT-PCR. These methods may be carried out according to conventional techniques.

(3) Cell Overexpressing Mutant FGFR2

According to the present invention, mutant FGFR2 comprises polypeptides comprising an amino acid sequence having one or a few amino acids deleted, substituted or added, or mutated by a combination thereof in a wild-type FGFR2 amino acid sequence such as the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2. Preferably, the mutant FGFR2 comprises polypeptides comprising an amino acid sequence having one or a few amino acids deleted, substituted or added, or mutated by a combination thereof in a wild-type FGFR2 amino acid sequence such as the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2, and having substantially the same activity as FGFR2. According to the present invention, a cell expressing mutant FGFR2 comprises cells expressing the above-mentioned polypeptides.

Examples of mutant FGFR2 include polypeptides comprising an amino acid sequence where serine at position 267 of the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2 is substituted by other amino acid, preferably proline (Cancer Research. 61, 3541-3543, 2001).

In addition, examples of mutant FGFR2 include polypeptides comprising a mutation site where a few amino acids at C-terminal are deleted in an amino acid sequence of wild-type FGFR2 such as amino acids 22-822 of the amino acid sequence represented by SEQ ID NO:2. Examples of mutant FGFR2 include polypeptides comprising an amino acid sequence where amino acids downstream from at least position 813, preferably at least position 784, more preferably at least position 780, and still more preferably at least position 769 are deleted from the amino acid sequence (amino acids 22-822) represented by SEQ ID NO:2.

Preferably, mutant FGFR2 is activating mutant FGFR2. Activating mutant FGFR2 refers to mutant FGFR2 that causes autophosphorylation in a ligand-independent manner and that activates intracellular signals.

The presence or the absence of FGFR2 mutation can be determined by analyzing the gene sequence of FGFR2 or the sequence of the transcript, i.e., mRNA, of FGFR2. An example of the method for analyzing a sequence includes dideoxynucleotide chain termination technique (Sanger et al., (1977) Proc. Natl. Acad. Sci. USA 74:5463). A sequence can also be analyzed by employing an appropriate DNA sequencer.

Furthermore, the presence or the absence of FGFR2 mutation can be analyzed, for example, by in situ hybridization, northern blot analysis, DNA microarray, RT-PCR, SSCP-PCR (Single-Strand Conformation Polymorphism-PCR) or the like. These methods may be carried out according to conventional techniques.

The presence or the absence of FGFR2 mutation can be analyzed, for example, by an immunochemical method (e.g., an immunohistochemistry method, immunoprecipitation, western blotting, flow cytometry, ELISA, RIA, etc.). These methods may be carried out according to conventional techniques.

According to the present invention, a cell expressing mutant FGFR2 is preferably an undifferentiated gastric cancer cell, more preferably at least one cell selected from the group consisting of poorly differentiated adenocarcinoma, signet-ring cell carcinoma, mucinous carcinoma and a scirrhous gastric cancer.

(4) FGFR2 Inhibitor of the Invention

Herein, a “halogen atom” refers to a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.

Preferable examples of a “halogen atom” include a fluorine atom and a chlorine atom.

Herein, a “C₁₋₆ alkyl group” refers to a linear or branched alkyl group with a carbon number of 1-6, specific examples including a methyl group, an ethyl group, a 1-propyl group (n-propyl group), a 2-propyl group (i-propyl group), a 2-methyl-1-propyl group (i-butyl group), a 2-methyl-2-propyl group (t-butyl group), a 1-butyl group (n-butyl group), a 2-butyl group (s-butyl group), a 1-pentyl group, a 2-pentyl group, a 3-pentyl group, a 2-methyl-1-butyl group, a 3-methyl-1-butyl group, a 2-methyl-2-butyl group, a 3-methyl-2-butyl group, a 2,2-dimethyl-1-propyl group, a 1-hexyl group, a 2-hexyl group, a 3-hexyl group, a 2-methyl-1-pentyl group, a 3-methyl-1-pentyl group, a 4-methyl-1-pentyl group, a 2-methyl-2-pentyl group, a 3-methyl-2-pentyl group, a 4-methyl-2-pentyl group, a 2-methyl-3-pentyl group, a 3-methyl-3-pentyl group, a 2,3-dimethyl-1-butyl group, a 3,3-dimethyl-1-butyl group, a 2,2-dimethyl-1-butyl group, a 2-ethyl-1-butyl group, a 3,3-dimethyl-2-butyl group and a 2,3-dimethyl-2-butyl group.

Preferable examples of a “C₁₋₆ alkyl group” include a methyl group, an ethyl group, a 1-propyl group, a 2-propyl group, a 2-methyl-1-propyl group, a 2-methyl-2-propyl group, a 1-butyl group and a 2-butyl group.

Herein, a “C₁₋₆ alkylene group” refers to a divalent group derived from a “C₁₋₆ alkyl group” defined above by removing any one hydrogen atom therefrom, specific examples including a methylene group, a 1,2-ethylene group, a 1,1-ethylene group, a 1,3-propylene group, a tetramethylene group, a pentamethylene group and a hexamethylene group.

Herein, a “C₂₋₆ alkenyl group” refers to a linear or branched alkenyl group having one double bond and a carbon number of 2-6, specific examples including an ethenyl group (vinyl group), a 1-propenyl group, a 2-propenyl group (allyl group), a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a pentenyl group and a hexenyl group.

Herein, a “C₂₋₆ alkynyl group” refers to a linear or branched alkynyl group having one triple bond and a carbon number of 2-6, specific examples including an ethinyl group, a 1-propynyl group, a 2-propynyl group, a 1-butynyl group, a 2-butynyl group, a 3-butynyl group, a pentynyl group and a hexynyl group.

Herein, a “C₃₋₈ cycloalkyl group” refers to a monocyclic or bicyclic saturated aliphatic hydrocarbon group with a carbon number of 3-8, specific examples including a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a bicyclo[2.1.0]pentyl group, a bicyclo[3.1.0]hexyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[4.1.0]heptyl group, a bicyclo[2.2.1]heptyl group (norbornyl group), a bicyclo[3.3.0]octyl group, a bicyclo[3.2.1]octyl group and a bicyclo[2.2.2]octyl group.

Preferable examples of a “C₃₋₈ cycloalkyl group” include a cyclopropyl group, a cyclobutyl group and a cyclopentyl group.

Herein, a “C₆₋₁₀ aryl group” refers to an aromatic hydrocarbon cyclic group with a carbon number of 6-10, specific examples including a phenyl group, a 1-naphthyl group, a 2-naphthyl group, an indenyl group and an azulenyl group.

A preferable example of a “C₆₋₁₀ aryl group” includes a phenyl group.

Herein, a “heteroatom” refers to a nitrogen atom, an oxygen atom or a sulfur atom.

Herein, a “5-10-membered heteroaryl group” refers to an aromatic cyclic group having 5-10 atoms forming the ring and 1-5 heteroatoms included in the atoms forming the ring, specific examples including a furyl group, a thienyl group, a pyrrolyl group, an imidazolyl group, a triazolyl group, a tetrazolyl group, a thiazolyl group, a pyrazolyl group, an oxazolyl group, an isoxazolyl group, an isothiazolyl group, a furazanyl group, a thiadiazolyl group, an oxadiazolyl group, a pyridyl group, a pyrazinyl group, a pyridazinyl group, a pyrimidinyl group, a triazinyl group, a purinyl group, a pteridinyl group, a quinolyl group, an isoquinolyl group, a naphthridinyl group, a quinoxalinyl group, a cinnolinyl group, a quinazolinyl group, a phthalazinyl group, an imidazopyridyl group, an imidazothiazolyl group, an imidazoxazolyl group, a benzothiazolyl group, a benzoxazolyl group, a benzimidazolyl group, an indolyl group, an isoindolyl group, an indazolyl group, a pyrrolopyridyl group, a thienopyridyl group, a furopyridyl group, a benzothiadiazolyl group, a benzoxadiazolyl group, a pyridopyrimidinyl group, a benzofuryl group, a benzothienyl group and a thienofuryl group.

Preferable examples of a “5-10-membered heteroaryl group” include a furyl group, a thienyl group, a pyrrolyl group, an imidazolyl group, a thiazolyl group, a pyrazolyl group, an oxazolyl group, an isoxazolyl group, an isothiazolyl group, a pyridyl group and a pyrimidinyl group.

Herein, a “3-10-membered nonaromatic heterocyclic group”:

(a) has 3-10 atoms forming the ring;

(b) has 1-2 heteroatoms included in the atoms forming the ring;

(c) may include 1-2 double bonds in the ring;

(d) may include 1-3 carbonyl groups, sulfinyl groups or sulfonyl groups in the ring; and

(e) is a nonaromatic monocyclic or bicyclic group where when a nitrogen atom is included in the atoms forming the ring, the nitrogen atom may have a chemical bond.

Specific examples include an aziridinyl group, an azetidinyl group, a pyrrolidinyl group, a piperidinyl group, an azepanyl group, an azocanyl group, a piperazinyl group, a diazepanyl group, a diazocanyl group, a diazabicyclo[2.2.1]heptyl group, a morpholinyl group, a thiomorpholinyl group, a 1,1-dioxothiomorpholinyl group, an oxiranyl group, an oxetanyl group, a tetrahydrofuryl group, a dioxolanyl group, a tetrahydropyranyl group, a dioxanyl group, a tetrahydrothienyl group, a tetrahydrothiopyranyl group, an oxazolidinyl group and a thiazolidinyl group.

Preferable examples of a “3-10-membered nonaromatic heterocyclic group” include an aziridinyl group, an azetidinyl group, a pyrrolidinyl group, a piperidinyl group, an azepanyl group, a piperazinyl group, a diazepanyl group, a morpholinyl group, a thiomorpholinyl group, a 1,1-dioxothiomorpholinyl group, a tetrahydrofuryl group and a tetrahydropyranyl group.

Herein, a “C₁₋₆ alkoxy group” refers to a group in which an oxygen atom is bound to the terminal of a “C₁₋₆ alkyl group” defined above, specific examples including a methoxy group, an ethoxy group, a 1-propoxy group (n-propoxy group), a 2-propoxy group (1-propoxy group), a 2-methyl-1-propoxy group (1-butoxy group), a 2-methyl-2-propoxy group (t-butoxy group), a 1-butoxy group (n-butoxy group), a 2-butoxy group (s-butoxy group), a 1-pentyloxy group, a 2-pentyloxy group, a 3-pentyloxy group, a 2-methyl-1-butoxy group, a 3-methyl-1-butoxy group, a 2-methyl-2-butoxy group, a 3-methyl-2-butoxy group, a 2,2-dimethyl-1-propoxy group, a 1-hexyloxy group, a 2-hexyloxy group, a 3-hexyloxy group, a 2-methyl-1-pentyloxy group, a 3-methyl-1-pentyloxy group, a 4-methyl-1-pentyloxy group, a 2-methyl-2-pentyloxy group, a 3-methyl-2-pentyloxy group, a 4-methyl-2-pentyloxy group, a 2-methyl-3-pentyloxy group, a 3-methyl-3-pentyloxy group, a 2,3-dimethyl-1-butoxy group, a 3,3-dimethyl-1-butoxy group, a 2,2-dimethyl-1-butoxy group, a 2-ethyl-1-butoxy group, a 3,3-dimethyl-2-butoxy group and a 2,3-dimethyl-2-butoxy group.

Preferable examples of a “C₁₋₆ alkoxy group” include a methoxy group, an ethoxy group, a 1-propoxy group, a 2-propoxy group, a 2-methyl-1-propoxy group, a 2-methyl-2-propoxy group, a 1-butoxy group and a 2-butoxy group.

Herein, a “C₁₋₆ alkylthio group” refers to a group in which a sulfur atom is bound to the terminal of a “C₁₋₆ alkyl group” defined above, specific examples including a methylthio group, an ethylthio group, a 1-propylthio group (n-propylthio group), a 2-propylthio group (i-propylthio group), a 2-methyl-1-propylthio group (1-butylthio group), a 2-methyl-2-propylthio group (t-butylthio group), a 1-butylthio group (n-butylthio group), a 2-butylthio group (s-butylthio group), a 1-pentylthio group, a 2-pentylthio group, a 3-pentylthio group, a 2-methyl-1-butylthio group, a 3-methyl-1-butylthio group, a 2-methyl-2-butylthio group, a 3-methyl-2-butylthio group, a 2,2-dimethyl-1-propylthio group, a 1-hexylthio group, a 2-hexylthio group, a 3-hexylthio group, a 2-methyl-1-pentylthio group, a 3-methyl-1-pentylthio group, a 4-methyl-1-pentylthio group, a 2-methyl-2-pentylthio group, a 3-methyl-2-pentylthio group, a 4-methyl-2-pentylthio group, a 2-methyl-3-pentylthio group, a 3-methyl-3-pentylthio group, a 2,3-dimethyl-1-butylthio group, a 3,3-dimethyl-1-butylthio group, a 2,2-dimethyl-1-butylthio group, a 2-ethyl-1-butylthio group, a 3,3-dimethyl-2-butylthio group and a 2,3-dimethyl-2-butylthio group.

Preferable examples of a “C₁₋₆ alkylthio group” include a methylthio group, an ethylthio group, a 1-propylthio group (n-propylthio group), a 2-propylthio group (1-propylthio group), a 2-methyl-1-propylthio group (1-butylthio group), a 2-methyl-2-propylthio group (t-butylthio group), a 1-butylthio group (n-butylthio group) and a 2-butylthio group (s-butylthio group).

Herein, a “C₃₋₈ cycloalkoxy group” refers to a group in which an oxygen atom is bound to the terminal of a “C₃₋₈ cycloalkyl group” defined above, specific examples including a cyclopropoxy group, a cyclobutoxy group, a cyclopentyloxy group, a cyclohexyloxy group, a cycloheptyloxy group, a cyclooctyloxy group, a bicyclo[2.1.0]pentyloxy group, a bicyclo[3.1.0]hexyloxy group, a bicyclo[2.1.1]hexyloxy group, a bicyclo[4.1.0]heptyloxy group, a bicyclo[2.2.1]heptyloxy group (norbornyloxy group), a bicyclo[3.3.0]octyloxy group, a bicyclo[3.2.1]octyloxy group and a bicyclo[2.2.2]octyloxy group.

Preferable examples of a “C₃₋₈ cycloalkoxy group” include a cyclopropoxy group, a cyclobutoxy group and a cyclopentyloxy group.

Herein, a “mono-C₁₋₆ alkylamino group” refers to a group in which a hydrogen atom in an amino group is substituted with a “C₁₋₆ alkyl group” defined above, specific examples including a methylamino group, an ethylamino group, a 1-propylamino group (n-propylamino group), a 2-propylamino group (i-propylamino group), a 2-methyl-1-propylamino group (1-butylamino group), a 2-methyl-2-propylamino group (t-butylamino group), a 1-butylamino group (n-butylamino group), a 2-butylamino group (s-butylamino group), a 1-pentylamino group, a 2-pentylamino group, a 3-pentylamino group, a 2-methyl-1-butylamino group, a 3-methyl-1-butylamino group, a 2-methyl-2-butylamino group, a 3-methyl-2-butylamino group, a 2,2-dimethyl-1-propylamino group, a 1-hexylamino group, a 2-hexylamino group, a 3-hexylamino group, a 2-methyl-1-pentylamino group, a 3-methyl-1-pentylamino group, a 4-methyl-1-pentylamino group, a 2-methyl-2-pentylamino group, a 3-methyl-2-pentylamino group, a 4-methyl-2-pentylamino group, a 2-methyl-3-pentylamino group, a 3-methyl-3-pentylamino group, a 2,3-dimethyl-1-butylamino group, a 3,3-dimethyl-1-butylamino group, a 2,2-dimethyl-1-butylamino group, a 2-ethyl-1-butylamino group, a 3,3-dimethyl-2-butylamino group and a 2,3-dimethyl-2-butylamino group.

Herein, a “di-C₁₋₆ alkylamino group” refers to a group in which two hydrogen atoms in an amino group are substituted with an identical or different “C₁₋₆ alkyl group” defined above, specific examples including a N,N-dimethylamino group, a N,N-diethylamino group, a N,N-di-n-propylamino group, a N,N-di-1-propylamino group, a N,N-di-n-butylamino group, a N,N-di-1-butylamino group, a N,N-di-s-butylamino group, a N,N-di-t-butylamino group, a N-ethyl-N-methylamino group, a N-n-propyl-N-methylamino group, a N-i-propyl-N-methylamino group, a N-n-butyl-N-methylamino group, a N-i-butyl-N-methylamino group, a N-s-butyl-N-methylamino group and a N-t-butyl-N-methylamino group.

Herein, a “C₂₋₇ acyl group” refers to a carbonyl group bound with a “C₁₋₆ alkyl group” defined above, specific examples including an acetyl group, a propionyl group, an isopropionyl group, a butyryl group, an isobutyryl group, a valeryl group, an isovaleryl group and a pivaloyl group.

Herein, a “C₂₋₇ alkoxycarbonyl group” refers to a carbonyl group bound with a “C₁₋₆ alkoxy group” defined above, specific examples including a methoxycarbonyl group, an ethoxycarbonyl group, a 1-propyloxycarbonyl group, a 2-propyloxycarbonyl group and a 2-methyl-2-propoxycarbonyl group.

Herein, “that may have a substituent” means “that may have one or more substituents in any combination at substitutable positions”, specific examples of substituents including a halogen atom, a hydroxyl group, a thiol group, a nitro group, a cyano group, a formyl group, a carboxyl group, an amino group, a silyl group, a methanesulfonyl group, a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a 5-10-membered heteroaryl group, a 3-10-membered nonaromatic heterocyclic group, a C₁₋₆ alkoxy group, a C₁₋₆ alkylthio group, a C₃₋₈ cycloalkoxy group, a mono-C₁₋₆ alkylamino group, a di-C₁₋₆ alkylamino group, a C₂₋₇ acyl group and a C₂₋₇ alkoxycarbonyl group. In this case, the C₁₋₆ alkyl group, the C₂₋₆ alkenyl group, the C₂₋₆ alkynyl group, the C₃₋₈ cycloalkyl group, the C₆₋₁₀ aryl group, the 5-10-membered heteroaryl group, the 3-10-membered nonaromatic heterocyclic group, the C₁₋₆ alkoxy group, the C₁₋₆ alkylthio group, the C₃₋₈ cycloalkoxy group, the mono-C₁₋₆ alkylamino group, the di-C₁₋₆ alkylamino group, the C₂₋₇ acyl group and the C₂₋₇ alkoxycarbonyl group may each independently have 1-3 groups selected from the group consisting of the following substituent groups.

<Substituent Groups>

A halogen atom, a hydroxyl group, a thiol group, a nitro group, a cyano group, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₆₋₁₀ aryl group, a 5-10-membered heteroaryl group, a 3-10-membered nonaromatic heterocyclic group, a C₁₋₆ alkoxy group and a C₁₋₆ alkylthio group.

According to the present invention, an example of a FGFR2 inhibitor includes a compound represented by General formula (I).

Hereinafter, a compound represented by General Formula (I) may also be referred to as a “FGFR2 inhibitor I”.

(i) R¹

R¹ represents a group represented by Formula —V¹—V²—V³ (wherein, V¹ represents an optionally substituted C₁₋₆ alkylene group; V² represents a single bond, an oxygen atom, a sulfur atom, a carbonyl group, a sulfinyl group, a sulfonyl group, a group represented by Formula —CONR⁶—, a group represented by Formula —SO₂NR⁶—, a group represented by Formula —NR⁶SO₂—, a group represented by Formula —NR⁶CO— or a group represented by Formula —NR⁶— (wherein, R⁶ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group or an optionally substituted C₃₋₈ cycloalkyl group); V³ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group).

A preferable example of R¹ includes a C₁₋₆ alkyl group provided that R¹ may have a substituent selected from a 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, a C₁₋₆ alkoxy group, an amino group, a mono-C₁₋₆ alkylamino group and a di-C₁₋₆ alkylamino group which may have a C₁₋₆ alkyl group.

More preferable examples of R¹ include a methyl group and a group represented by any one of the following formulae

(wherein, R^(a3) represents a methyl group; R^(a1) represents a hydrogen atom or a hydroxyl group; R^(a2) represents a methoxy group, an ethoxy group, a 1-pyrrolidinyl group, a 1-piperidinyl group, a 4-morpholinyl group, a dimethylamino group or a diethylamino group).

Still more preferable examples of R¹ include a methyl group and a 2-methoxyethyl group.

(ii) R²

R² represents a cyano group, an optionally substituted C₁₋₆ alkoxy group, a carboxyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group; V^(a12) represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group, an optionally substituted 3-10-membered nonaromatic heterocyclic group, a hydroxyl group, an optionally substituted C₁₋₆ alkoxy group or an optionally substituted C₃₋₈ cycloalkoxy group).

Preferable examples of R² include a cyano group or a group represented by Formula —CONV^(a11)V^(a12) (wherein, V^(a11) and V^(a12) have the same meaning as defined above).

More preferable examples of R² include a cyano group or a group represented by Formula —CONHV^(a16) (wherein, V^(a16) represents a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group, a C₁₋₆ alkoxy group or a C₃₋₈ cycloalkoxy group, provided that V^(a16) may have a substituent selected from a halogen atom, a cyano group, a hydroxyl group and a C₁₋₆ alkoxy group).

A still more preferable example of R² includes a group represented by Formula —CONHV^(a17) (wherein, V^(a17) represents a hydrogen atom, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group).

The most preferable example of R² includes a group represented by Formula —CONHV^(a18) (wherein, V^(a18) represents a hydrogen atom, a methyl group or a methoxy group).

(iii) Y¹

Y¹ represents a group represented by the following formula

(wherein, R⁷ and R⁸ each independently represent a hydrogen atom, a halogen atom, a cyano group, a nitro group, an amino group, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₁₋₆ alkoxy group, an optionally substituted C₁₋₆ alkylthio group, a formyl group, an optionally substituted C₂₋₇ acyl group, an optionally substituted C₂₋₇ alkoxycarbonyl group or a group represented by Formula —CONV^(d1)V^(d2) (wherein, V^(d1) and V^(d2) each independently represent a hydrogen atom or an optionally substituted C₁₋₆ alkyl group); W¹ and W² each independently represent an optionally substituted carbon atom or nitrogen atom).

A preferable example of Y¹ includes a group represented by the following formula

(wherein, R⁷¹ represents a hydrogen atom or a halogen atom).

(iv) R³ and R⁴

R³ and R⁴ each independently represent a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₂₋₇ acyl group or an optionally substituted C₂₋₇ alkoxycarbonyl group.

A preferable example of R³ and R⁴ includes a hydrogen atom.

(v) R⁵

R⁵ represents a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group, an optionally substituted 5-10-membered heteroaryl group or an optionally substituted 3-10-membered nonaromatic heterocyclic group.

Preferable examples of R⁵ include a hydrogen atom, an optionally substituted C₁₋₆ alkyl group, an optionally substituted C₂₋₆ alkenyl group, an optionally substituted C₂₋₆ alkynyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted C₆₋₁₀ aryl group and an optionally substituted 3-10-membered nonaromatic heterocyclic group.

More preferable examples of R⁵ include a hydrogen atom, a C₁₋₆ alkyl group, a C₃₋₈ cycloalkyl group and a C₆₋₁₀ aryl group (provided that R⁵ may have at least one substituent selected from the group consisting of a halogen atom and a methanesulfonyl group).

More preferable examples of R⁵ include a methyl group, an ethyl group and a cyclopropyl group.

Furthermore, preferable examples of the compound represented by General Formula (I) include:

-   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-(4-fluorophenyl)urea; -   N-(2-chloro-4-((6-cyano-7-((1-methyl-4-piperidyl)methoxy)-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N-(4-((6-cyano-7-(((2R)-3-(diethylamino)-2-hydroxypropyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   N-(4-((6-cyano-7-(((2R)-2-hydroxy-3-(1-pyrrolidino)propyl)oxy)-4-quinolyl)oxy)phenyl)-N′-(4-fluorophenyl)urea; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-cyclopropyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-methoxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-fluoroethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-ethyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-((2S)-2,3-dihydroxypropyl)oxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-ethoxyethoxy)-6-quinolinecarboxamide; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N-(2-fluoro-4-((6-carbamoyl-7-methoxy-4-quinolyl)oxy)phenyl)-N′-cyclopropyl     urea; -   N6-(2-hydroxyethyl)-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(1-propylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cis-2-fluoro-cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-(4-morpholino)ethoxy)-6-quinolinecarboxamide; -   4-(3-chloro-4-(2-fluoroethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-((2R)tetrahydro-2-furanylmethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-3-diethylamino-2-hydroxypropoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((2R)-2-hydroxy-3-(1-pyrrolidino)propoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N6-methyl-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-((1-methyl-4-piperidyl)methoxy)-6-quinolinecarboxamide; -   N-(4-(6-cyano-7-(2-methoxyethoxy)-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea; -   N-(4-(6-cyano-7-(3-(4-morpholino)propoxy)-4-quinolyl)oxyphenyl)-N′-(3-(methylsulfonyl)phenyl)urea; -   4-(4-((cyclopropylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-fluoro-4-((2-fluoroethylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-(2-ethoxyethyl)-4-(3-chloro-4-(((methylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(4-(3-ethylureido)-3-fluoro-phenoxy)-7-methoxyquinoline-6-carboxylic     acid (2-cyanoethyl)amide; and -   N-(4-(6-(2-cyanoethyl)carbamoyl-7-methoxy-4-quinolyl)oxy-2-fluorophenyl)-N′-cyclopropyl     urea.

More preferable examples of the compound represented by General Formula (I) include:

-   4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; -   N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; -   4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide;     and -   N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide.

A still more preferable example of the compound represented by General Formula (I) includes 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (see Formula (II)).

The most preferable example of the FGFR2 inhibitor I includes methanesulfonate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.

A compound represented by General formula (I) may be produced by a known method such as methods described in International Publications Nos. 02/32872 (WO02/32872) and 2005/063713 (WO2005/063713).

In addition, a FGFR2 inhibitor according to the present invention may not be a compound represented by General Formula (I) above (hereinafter, also referred to as a “FGFR2 inhibitor II”) as long as it has an activity of inhibiting the kinase activity of FGFR2. Examples of FGFR2 inhibitors II include:

5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (hereinafter, also referred to as “SU11248”; Journal of Medicinal Chemistry., 46:1116-9, 2003, WO 01/060814) (see Formula (III)),

N-(3-trifluoromethyl-4-chlorophenyl)-N′-(4-(2-methylcarbamoylpyridine-4-yl)oxyphenyl)urea (hereinafter, also referred to as “BAY 43-9006” or “sorafenib”; WO00/42012) (see Formula (IV)),

6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridine-2-yl)ethenyl]indazole (hereinafter, also referred to as “AG013736”; WO0/002369) (see Formula (V)), and

N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl)urea (hereinafter, also referred to as “KRN951”; WO02/088110) (see Formula (VI))

SU11248, BAY 43-9006, AG013736 and KRN951 may be produced by a known method such as methods described in respective publications mentioned above.

According to the present invention, a FGFR2 inhibitor may form a pharmacologically acceptable salt with acid or base. The FGFR2 inhibitor of the invention also comprises such pharmacologically acceptable salts. Examples of salts formed with acids include inorganic acid salts such as hydrochloride salts, i salts, sulfate salts and phosphate salts, and organic acid salts such as formic acid, acetic acid, lactic acid, succinic acid, fumaric acid, maleic acid, citric acid, tartaric acid, stearic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and trifluoroacetic acid. Examples of salts formed with bases include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, organic base salts such as trimethylamine, triethylamine, pyridine, picoline, dicyclohexylamine, N,N′-dibenzyl ethylenediamine, arginine and lysine and ammonium salts.

Furthermore, according to the present invention, the FGFR2 inhibitor may exist as a solvate or an optical isomer. According to the present invention, the FGFR2 inhibitor comprises such solvates and optical isomers. Examples of solvates include hydrates and nonhydrates, preferably hydrates. Examples of solvents include water, alcohols (for example, methanol, ethanol and n-propanol) and dimethylformamide.

Moreover, according to the present invention, the FGFR2 inhibitor may be crystalline or amorphous. If a crystalline polymorph exists, it may exist as one type of any crystalline or mixture thereof.

According to the present invention, the FGFR2 inhibitor also comprises their metabolites generated by undergoing metabolism such as oxidation, reduction, hydrolysis and conjugation in vivo. According to the present invention, the FGFR2 inhibitor also comprises compounds that generate the FGFR2 inhibitor by undergoing metabolism such as oxidation, reduction and hydrolysis in vivo.

Preferably, the FGFR2 inhibitor of the invention is a substance that has an activity of inhibiting the FGFR2 kinase activity (hereinafter, also referred to as an “FGFR2 inhibitory activity”). Herein, an “FGFR2 kinase activity” refers to an activity of FGFR2 to phosphorylate a tyrosine residue of own protein or other protein.

Examples of methods for determining a FGFR2 inhibitory activity of the FGFR2 inhibitor include cell free kinase assay, western blotting, cell growth assay and viability assay. Examples of the cell growth assay include tritium thymidine uptake method, MTT method, XTT method (cell counting kit-8 (Dojindo Laboratories)), AlamarBlue technique, Neutral Red technique, BrdU technique, Ki67 staining and PCNA staining. Examples of the viability assay include TUNNEL staining, Caspase-3 cleavage detection and PARP cleavage detection. These methods may be carried out according to conventional techniques (Blood. 2005, 105, 2941-2948., Molecular Cancer Therapeutics. 2005, 4, 787-798).

Hereinafter, an exemplary method for determining a FGFR2 inhibitory activity will be described.

The FGFR2 inhibitory activity can be determined by cell free kinase assay.

FGFR2 can be prepared by a gene-engineering technique according to a conventional method. For example, according to the method of Baculovirus Expression System, human recombinant GST fusion protein, human recombinant histidine-tag fusion protein or the like may be expressed in an insect cell (Spondoptea frugiperda 9 (Sf9)). Furthermore, the expressed recombinant protein can be purified by affinity chromatography (e.g., GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen)). The purity and identification of the protein can be confirmed by SDS-PAGE, silver staining and western blotting using an antibody specific to FGFR2.

The cell free kinase assay may be carried out as follows.

First, to each well of a plate (e.g., 96-well, 384-well, etc.), 25 μl of a solution containing an ATP solution, a test substance, 5-10 mU of FGFR2 recombinant protein and 0.1 mg/ml Poly(Glu, Tyr)_(4:1) may be added. To this mixture, MgATP is added to initiate reaction.

25 μl of this mixture may contain 8 mM MOPS (pH 7.0), 0.2 mM EDTA, 2.5 mM MnCl₂, 10 mM Mg acetate and the like. ATP used in this case may be labeled with a radioisotope such as [γ-³²P]-ATP and [γ-³³P]-ATP.

The reaction may be terminated by adding 5 μL of 3% phosphoric acid following incubation for a given period of time.

Each well may be subjected to an appropriate washing procedure.

A FGFR2 inhibitory activity can be assessed by determining the amount of ATP incorporation. When a radioactive isotope-labeled ATP mentioned above is used, the amount of ATP incorporation can be assessed by determination of the radioactivity captured on the plate with a scintillation counter. Alternatively, a certain amount of the reaction solution may be spotted onto a filter to measure the radioactivity thereof with a scintillation counter. The filter may be subjected to an appropriate washing procedure.

The FGFR2 inhibitory activity of the compound can be assessed by this method.

2. Therapeutic Substance for Gastric Cancer

According to the present invention, a therapeutic substance for gastric cancer is not particularly limited as long as it is a substance used for treating gastric cancer, a substance whose therapeutic use is suitable for gastric cancer or a substance having anti-tumor action against gastric cancer. In addition, the therapeutic substance for gastric cancer of the invention may be a therapeutic drug for gastric cancer obtained by formulating the compound as an active ingredient.

According to the present invention, examples of therapeutic substances for gastric cancer include carboquone, nimustine, 5-fluorouracil analogs (e.g., 5-fluorouracil, tegafur, UFT, doxifluridine and carmofur, S-1), doxorubicin (adriamycin), mitomycin C, aclarubicin, pirarubicin, epirubicin, irinotecan, paclitaxel analogs (e.g., docetaxel and paclitaxel), cis-platinum (Cisplatin)), preferably 5-fluorouracil, S-1, irinotecan, docetaxel, paclitaxel or cis-platinum, more preferably, irinotecan, 5-fluorouracil or paclitaxel. Therapeutic substances for gastric cancer may be produced according to a known method or they may be purchased.

Carboquone is available by purchasing Esquinon (Registered Trademark) (Sankyo).

Nimustine or nimustine hydrochloride is available by purchasing Nidran (Registered Trademark) (Sankyo).

5-Fluorouracil is available by purchasing 5-FU (Kyowa Hakko).

Tegafur is available by purchasing Futraful (Registered Trademark) (Taiho Pharmaceutical Co., Ltd.).

UFT refers to a combinational agent of tegafur and uracil. UFT is available by purchasing UFT (Registered Trademark) (Taiho Pharmaceutical Co., Ltd.).

Doxifluridine is available by purchasing Furtulon (Registered Trademark) (Chugai Pharmaceutical Co., Ltd.).

Carmofur is available by purchasing Mifurol (Registered Trademark) (Schering).

S-1 refers to a combinational agent of tegafur, gemeracil and oteracil potassium. S-1 is available by purchasing TS-1 (Registered Trademark) (Taiho Pharmaceutical Co., Ltd.).

Doxorubicin (adriamycin) or doxorubicin hydrochloride is available by purchasing Adriacin (Registered Trademark) (Kyowa Hakko).

Mitomycin C is available by purchasing mitomycin (Kyowa Hakko).

Aclarubicin or aclarubicin hydrochloride is available by purchasing Aclacinon (Registered Trademark) (Astellas Inc.).

Pirarubicin or pirarubicin hydrochloride is available by purchasing Pinorubin (Registered Trademark) (Nippon Kayaku Co., Ltd.) or Therarubicin (Registered Trademark) (Meiji Seika Kaisya, Ltd.).

Epirubicin or epirubicin hydrochloride is available by purchasing Farmorubicin (Registered Trademark) (Kyowa Hakko) or Epirubicin (Registered Trademark) (Nippon Kayaku Co., Ltd.).

Irinotecan or irinotecan hydrochloride is available by purchasing Campto (Registered Trademark) (Yakult). It is also available by purchasing Topotecin (Registered Trademark) (Daiichi Seiyaku).

Docetaxel or docetaxel hydrate is available by purchasing Taxoere (Registered Trademark) (Sanofi-aventis).

Paclitaxel is available by purchasing Taxol (Registered Trademark) (Bristol-Myers Squibb Company) or by purchasing Paclitaxel (Nippon Kayaku Co., Ltd.) or Paclitaxel (Calbiochem).

Cis-platinum (Cisplatin) is available by purchasing Randa (Registered Trademark) (Nippon Kayaku Co., Ltd.) or Briplatin (Registered Trademark) (Bristol-Myers Squibb Company).

Since a FGFR2 inhibitor of the present invention has an anti-tumor action against undifferentiated gastric cancer, it is also comprised in the therapeutic substances for gastric cancer. In this case, the therapeutic substance for gastric cancer is preferably a FGFR2 inhibitor I or II, and more preferably a FGFR inhibitor II.

According to the present invention, the therapeutic substance for gastric cancer may form a pharmacologically acceptable salt with acid or base. The therapeutic substance for gastric cancer according to the invention also comprises such pharmacologically acceptable salts. Examples of salts formed with acids include inorganic acid salts such as hydrochloride salts, hydrobromate salts, sulfate salts and phosphate salts, and organic acid salts such as formic acid, acetic acid, lactic acid, succinic acid, fumaric acid, maleic acid, citric acid, tartaric acid, stearic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and trifluoroacetic acid. Examples of salts formed with bases include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, organic base salts such as trimethylamine, triethylamine, pyridine, picoline, dicyclohexylamine, N,N′-dibenzyl ethylenediamine, arginine and lysine, and ammonium salts.

Furthermore, according to the present invention, the therapeutic substance for gastric cancer may exist as a solvate or an optical isomer. According to the present invention, the therapeutic substance for gastric cancer comprises such solvates and optical isomers. Examples of solvates include hydrates and nonhydrates, preferably hydrates. Examples of solvents include water, alcohols (for example, methanol, ethanol and n-propanol) and dimethylformamide.

Moreover, according to the present invention, the therapeutic substance for gastric cancer may be crystalline or amorphous. If a crystalline polymorph exists, it may exist as one type of any crystalline forms or mixture thereof.

According to the present invention, the therapeutic substance for gastric cancer also comprises their metabolites generated by undergoing metabolism such as oxidation, reduction, hydrolysis and conjugation in vivo. According to the present invention, the therapeutic substance for gastric cancer also comprises compounds that generate the therapeutic substance for gastric cancer by undergoing metabolism such as oxidation, reduction and hydrolysis in vivo.

3. Pharmaceutical Composition, Therapeutic Agent, Kit and Therapeutic Method

The present invention is characterized in that a FGFR2 inhibitor is combined with a therapeutic substance for gastric cancer. Specifically, the present invention relates to a therapeutic agent, a kit and a therapeutic method for undifferentiated gastric cancer characterized in that the followings are combined: (i) a FGFR2 inhibitor I and a therapeutic substance for gastric cancer; (ii) a FGFR2 inhibitor I and a FGFR2 inhibitor II; or (iii) a FGFR2 inhibitor II and a therapeutic substance for gastric cancer. Preferably, the therapeutic agent of the invention is used for a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

Herein, undifferentiated gastric cancer comprises poorly differentiated adenocarcinoma, signet-ring cell carcinoma and mucinous carcinoma (Japanese Classification of Gastric Carcinoma “Igan-Toriatsukai Kiyaku” (13th ed.)). In the case of undifferentiated gastric cancer, cancer cells are likely to diffuse and likely to develop fibrosis that leads to scirrhous gastric cancer. Thus, the therapeutic agent of the invention is effective against at least one gastric cancer selected from the group consisting of poorly differentiated adenocarcinoma, signet-ring cell carcinoma, mucinous carcinoma and scirrhous gastric cancer.

The therapeutic agent of the invention may be administered to a mammal (e.g., human, rat, rabbit, sheep, pig, bovine, cat, dog, monkey, etc.).

The pharmaceutical composition of the invention comprises a FGFR2 inhibitor and a therapeutic substance for gastric cancer, specifically, (i) a FGFR2 inhibitor I and a therapeutic substance for gastric cancer; (ii) a FGFR2 inhibitor I and a FGFR2 inhibitor II; or (iii) a FGFR2 inhibitor II and a therapeutic substance for gastric cancer, which is administered to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2.

The pharmaceutical composition of the invention may be used as a therapeutic agent for a disease characterized by comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2. An example of such a disease includes undifferentiated gastric cancer.

The pharmaceutical composition of the invention may be administered to a living organism, i.e., a mammal (e.g., human, rat, rabbit, sheep, pig, bovine, cat, dog, monkey, etc.). These living organisms of the present invention may comprise either a cell overexpressing FGFR2 or a cell expressing mutant FGFR2, or both of them.

According to the present invention, treatment comprises relieving symptoms of the disease, retarding progression of the disease, eliminating symptoms of the disease, improving prognosis of the disease and preventing recurrence of the disease.

According to the present invention, a therapeutic agent for cancer also comprises anti-tumor agents, agents for suppressing cancer metastasis, agents for improving cancer prognosis, agents for preventing of cancer recurrence and the like.

The effect of treatment may be confirmed by observation of an x-ray picture, CT or the like, by histopathological diagnosis by biopsy or according to tumor marker values.

According to the present invention, a FGFR2 inhibitor is as described in “1. FGFR2 inhibitor”. The FGFR2 inhibitor of the invention is, for example, a FGFR2 inhibitor I such as a compound represented by General Formula (I), more preferably, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, and more preferably methanesulfonate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.

On the other hand, the FGFR2 inhibitor of the invention is a FGFR2 inhibitor II, a substance that shows FGFR2 inhibitory activity and is not comprised in compounds represented by General Formula (I), which is preferably SU11248, BAY43-9006, AG013736 or KRN951.

According to the present invention, a therapeutic substance for gastric cancer is as described in “2. Therapeutic substance for gastric cancer”, and it is preferably irinotecan, 5 or paclitaxel. Since a FGFR2 inhibitor has an anti-tumor activity against undifferentiated gastric cancer, it may be included in a therapeutic substance for gastric cancer.

Preferable embodiments of combinations of FGFR2 inhibitors and therapeutic substances for gastric cancer according to the present invention are described below.

(1) According to the present invention, when a FGFR2 inhibitor is a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof (a FGFR2 inhibitor I), it is preferably used in combination with a therapeutic substance for gastric cancer described in “2. Therapeutic substance for gastric cancer” above.

(2) According to the present invention, when a FGFR2 inhibitor is a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof (a FGFR2 inhibitor I), it is preferably used in combination with a FGFR2 inhibitor that is not comprised in compounds represented by General Formula (I) (FGFR2 inhibitors II) such as SU11248, BAY43-9006, AG03736, KRN951 or the like.

(3) According to the present invention, when a FGFR2 inhibitor is a FGFR2 inhibitor that is not comprised in compounds represented by General Formula (I) (FGFR2 inhibitors II), it is preferably used in combination with a therapeutic substance for gastric cancer described in “2. Therapeutic substance for gastric cancer” above.

According to the present invention, the phrase “in combination” refers to a combination of compounds for combination use, and includes both modes where separate substances are used in combination upon administration or where they are provided as a mixture.

The therapeutic agent of the invention is also provided in a form of a therapeutic agent for undifferentiated gastric cancer comprising a FGFR2 inhibitor I for administration to a patient in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor II. Furthermore, the therapeutic agent of the invention is also provided in a form of a therapeutic agent for treating undifferentiated gastric cancer comprising a FGFR2 inhibitor II or in a form of a therapeutic agent for treating gastric cancer comprising a therapeutic substance for gastric cancer, for administration to a patient in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor II.

Moreover, a pharmaceutical composition of the invention is also provided in a form of a pharmaceutical composition comprising a FGFR2 inhibitor I for administration to a patient in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor II, for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2. The pharmaceutical composition of the invention is also provided in a form of a pharmaceutical composition comprising a FGFR2 inhibitor II or a therapeutic substance for gastric cancer for administration to a patient in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor II, for administration to the above-mentioned living organism.

A FGFR2 inhibitor I and a therapeutic substance for gastric cancer or a FGFR2 inhibitor II, or a FGFR2 inhibitor II and a therapeutic substance for gastric cancer may be administered simultaneously or separately. The term “simultaneously” means that they are administered at the same timing in a single administration schedule and does not necessarily mean that they are administered at exactly the same moment. The term “separately” means that they are administered at different timings in a single administration schedule.

The kit of the present invention is characterized by comprising a set of a formulation comprising a FGFR2 inhibitor I and a formulation comprising a therapeutic substance for gastric cancer or a FGFR2 inhibitor II. In addition, the kit of the present invention is characterized by comprising a set of a formulation comprising a FGFR2 inhibitor II and a formulation comprising a therapeutic substance for gastric cancer. The form of the formulations comprised in the kit of the invention is not particularly limited as long as they contain the substances mentioned above. The kit of the invention is useful as a kit for treating undifferentiated gastric cancer.

The formulations in the kit of the invention may be mixed together, or they may be kept separately and packed together. These formulations may be administered simultaneously or one after the other.

The therapeutic agent, the pharmaceutical composition, the kit or the method for treating undifferentiated gastric cancer of the invention may further include one or more other anti-tumor agents in combination. Such anti-tumor agents are not particularly limited as long as they have an anticancer activity.

The therapeutic agent, the pharmaceutical composition or the kit of the invention may be administered either orally or parenterally.

Upon use of the therapeutic agent, the pharmaceutical composition or the kit of the invention, the given dose of the FGFR2 inhibitor differs depending on the degree of the symptom, age, sex, weight and sensitivity difference of the patient, administration mode, administration period, administration interval, nature, prescription and type of the pharmaceutical formation and the type of the active ingredient. Usually, but without limitation, the dose is 0.1-1000 mg/day, preferably 0.5-100 mg/day and more preferably 1-30 mg/day for an adult (weight 60 kg), which may be usually administered once to three times a day.

Upon use of the therapeutic agent, the pharmaceutical composition or the kit of the invention, the given dose of the therapeutic substance for gastric cancer is usually, but without limitation, 0.1-6000 mg/day, preferably 10-4000 mg/day and more preferably 50-2000 mg/day for an adult (weight 60 kg), which may be usually administered once to three times a day.

The amount of the FGFR2 inhibitor I used is not particularly limited, and differs depending on the individual combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor II. For example, the amount of the FGFR2 inhibitor I is about 0.01-100 times (weight ratio), more preferably about 0.1-10 times (weight ratio) the amount of the therapeutic substance for gastric cancer or the FGFR2 inhibitor II.

Similarly, the amount of the FGFR2 inhibitor II used is not particularly limited, and differs depending on the combination with a therapeutic substance for gastric cancer. For example, the amount of the FGFR2 inhibitor II is about 0.01-100 times (weight ratio), more preferably about 0.1-10 times (weight ratio) the amount of the therapeutic substance for gastric cancer.

Although the pharmaceutical composition or the therapeutic agent of the invention may be used directly, they are generally made into formulations while mixing with appropriate additives.

A FGFR2 inhibitor or a therapeutic substance for gastric cancer contained in the kit of the invention may be made into a formulation while mixing with appropriate additives.

Examples of such additives include excipients, binders, lubricants, disintegrants, colorants, flavoring agents, emulsifiers, surfactants, solubilizing agents, suspending agents, tonicity agents, buffers, antiseptic agents, antioxidant agents, stabilizers, absorption promoters and the like that are generally used for medicine. If required, they may be used in combination. Examples of such additive are mentioned below.

Excipients: lactose, sucrose, glucose, cornstarch, mannitol, sorbitol, starch, alpha-starch, dextrin, crystalline cellulose, light anhydrous silicic acid, aluminum silicate, calcium silicate, magnesium aluminometasilicate and calcium hydrogen phosphate.

Binders: for example, polyvinyl alcohol, methyl cellulose, ethyl cellulose, gum arabic, tragacanth, gelatin, shellack, hydroxypropyl methylcellulose, hydroxypropylcellulose, carboxymethylcellulose sodium, polyvinylpyrrolidone and macrogol.

Lubricants: magnesium stearate, calcium stearate, sodium stearyl fumarate, talc, polyethyleneglycol and colloid silica.

Disintegrants: crystalline cellulose, agar, gelatin, calcium carbonate, sodium hydrogen carbonate, calcium citrate, dextrin, pectin, low substituted hydroxypropylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, carboxymethyl starch and carboxymethyl starch sodium.

Colorants: ferric oxide, yellow ferric oxide, carmine, caramel, beta-carotene, titanium oxide, talc, riboflavin sodium phosphate, yellow aluminum lake and the like that are approved as additives in drugs.

Flavoring agents: cocoa powder, menthol, aromatic acid, peppermint oil, camphor and cinnamon powder.

Emulsifiers and surfactants: stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionate, lecithin, glycerine monostearate, sucrose fatty acid ester and glycerine fatty acid ester.

Solubilizing agents: polyethyleneglycol, propylene glycol, benzyl benzoate, ethanol, cholesterol, triethanolamine, sodium carbonate, sodium citrate, Polysorbate 80 and nicotine acid amide.

Suspending agents: for example, in addition to the surfactants mentioned above, hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and the like.

Tonicity agents: glucose, sodium chloride, mannitol and sorbitol.

Buffers: buffers such as phosphate, acetate, carbonate, citrate and the like.

Antiseptic agents: methylparaben, propylparaben, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid and sorbic acid.

Antioxidant agents: hydrosulfate, ascorbic acid and alpha-tocopherol.

Stabilizers: those generally used for medicine.

Absorption promoters: those generally used for medicine.

If required, components such as vitamins and amino acids may be blended.

Examples of the above-mentioned formulations include oral formulations such as tablets, powder, granule, fine granule, capsule, syrup, lozenge and inhaler; external formulations such as suppository, ointment, eye ointment, poultice strip, eye-drops, nasal drops, eardrops, skin patch and lotion; and injectable formulations.

The oral formulations mentioned above may be formulated by appropriately combining the additives mentioned above. If necessary, surface of these formulations may be coated.

The external formulations mentioned above may be formulated by appropriately combining the additives mentioned above, particularly excipients, binders, flavoring agents, emulsifiers, surfactants, solubilizing agents, suspending agent, tonicity agents, antiseptic agents, antioxidant agents, stabilizers and absorption promoters.

The injectable formulations mentioned above may be formulated by appropriately combining the additives mentioned above, particularly emulsifiers, surfactants, solubilizing agents, suspending agents, tonicity agents, buffers, antiseptic agents, antioxidant agents, stabilizers and absorption promoters. The injectable formulations may be used through means such as infusion, intramuscular injection, subcutaneous injection, intradermal injection and intravenous injection.

The therapeutic agent, the pharmaceutical composition or the kit of the invention can also comprise a packaging container, an instruction, a package insert or the like in addition to the FGFR2 inhibitor and/or the therapeutic substance for gastric cancer mentioned above. The packaging container, the instruction, the package insert or the like may be printed with description of a combination for using the compounds in combination, and description of usage and dose for using separate substances in combination upon administration or for use of them as a mixture. The usage and dose may be described by referring to the description above.

The kit of the invention may comprise: (a) at least one selected from the group consisting of a packaging container, an instruction and a package insert describing combination use of a FGFR2 inhibitor I with a therapeutic substance for gastric cancer or a FGFR2 inhibitor II; and (b) a therapeutic agent for undifferentiated gastric cancer comprising the FGFR2 inhibitor I. Moreover, the kit of the invention may comprise: (a)′ at least one selected from the group consisting of a packaging container, an instruction and a package insert describing combination use of a FGFR2 inhibitor II with a therapeutic substance for gastric cancer; and (b)′ a therapeutic agent for undifferentiated gastric cancer comprising the FGFR2 inhibitor II or a therapeutic agent for treating gastric cancer comprising the therapeutic substance for gastric cancer.

The kit of the invention may comprise: (a) above; and (b)″ a pharmaceutical composition comprising a FGFR2 inhibitor I for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2. In addition, the kit of the invention may comprise: (a)′ above; and (b)′″ a pharmaceutical composition comprising a FGFR2 inhibitor II or a therapeutic substance for gastric cancer for administration to the above-mentioned living organism.

These kits are useful for treating undifferentiated gastric cancer. The packaging container, the instruction, the package insert of the like may be printed with description for using the substances in combination, and description of usage and dose for using separate substances in combination upon administration or for use of them as a mixture. The usage and dose may be determined by referring to the descriptions of the therapeutic agent, the pharmaceutical composition and the kit above.

The present invention also comprises a method for treating undifferentiated gastric cancer characterized by administering effective dosages of a FGFR2 inhibitor I and a therapeutic substance for gastric cancer or a FGFR2 inhibitor II to a patient. The present invention also comprises a method for treating undifferentiated gastric cancer characterized by administering effective dosages of a FGFR2 inhibitor II and a therapeutic substance for gastric cancer to a patient.

Furthermore, the present invention comprises a method for treating a disease characterized by administering effective dosages of a FGFR2 inhibitor I and a therapeutic substance for gastric cancer or a FGFR2 inhibitor II to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2. The present invention also comprises a method for treating a disease characterized by administering effective dosages of a FGFR2 inhibitor II and a therapeutic substance for gastric cancer to the living organism. According to the present invention, the disease is preferably undifferentiated gastric cancer.

According to the therapeutic method of the invention, the route and the method for administering the FGFR2 inhibitor are not particularly limited but reference may be made to the description of the pharmaceutical composition or the therapeutic agent of the invention above.

The present invention comprises use of a FGFR2 inhibitor I for producing a therapeutic agent for undifferentiated gastric cancer in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor II. The present invention also comprises use of a FGFR2 inhibitor II or a therapeutic substance for gastric cancer for producing a therapeutic agent for undifferentiated gastric cancer in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor II.

In addition, the present invention comprises use of a FGFR2 inhibitor I for producing a pharmaceutical composition in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor II for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2. The present invention also comprises use of a FGFR2 inhibitor II or a therapeutic substance for gastric cancer for producing a pharmaceutical composition in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor II for administration to the above-mentioned living organism. According to the use of the invention, the pharmaceutical composition is useful as a therapeutic agent for undifferentiated gastric cancer.

The present invention comprises a FGFR2 inhibitor I for a therapeutic agent for undifferentiated gastric cancer in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor II. The present invention also comprises a FGFR2 inhibitor II or a therapeutic substance for gastric cancer for a therapeutic agent for undifferentiated gastric cancer in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor II.

Moreover, the present invention comprises a FGFR2 inhibitor I for a pharmaceutical composition in combination with a therapeutic substance for gastric cancer or a FGFR inhibitor II for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2. The present invention also comprises a FGFR2 inhibitor II or a therapeutic substance for gastric cancer for a pharmaceutical composition in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor II for administration to the above-mentioned living organism. According to the present invention, the pharmaceutical composition is useful as a therapeutic agent for undifferentiated gastric cancer.

Hereinafter, the present invention will be illustrated by way of specific examples, although the invention should not be limited thereto.

Example 1 Combination Use of the Compound of the Invention and Irinotecan Hydrochloride in Subcutaneous Transplanted (Xenograft) Models (In Vivo) of Human Scirrhous Gastric Cancer Cell Line (HSC-39)

Human scirrhous gastric cancer cell line HSC-39 (purchased from Immuno-Biological Laboratories Co,. Ltd.) was cultured in RPMI1640 (containing 10% FBS) in a 5% carbon dioxide gas incubator at 37° C. to about 80% confluence, and then the cells were collected with trypsin-EDTA. A 5×10⁷ cells/mL suspension was prepared with a phosphate buffer, and each 0.1 mL of the resulting cell suspension was subcutaneously transplanted to nude mice at the side of their bodies.

Twelve days after the transplantation, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (3, 10 or 30 mg/kg, once a day for four weeks, oral) and irinotecan hydrochloride (Daiichi Seiyaku) (100 mg/kg, every four days for three times, intravenous) were administered alone or in combination. The major and minor axes of tumors were measured with Digimatic caliper (Mitsutoyo Corporation), and tumor volumes and relative tumor volumes were calculated according to the following formulae:

Tumor Volume (TV)=Major axis of tumor (mm)×(Minor axis of tumor)² (mm²)/2

Relative Tumor Volume (RTV)=Tumor volume on measurement day/Tumor volume on the first administration day.

If statistically significant interaction was observed in the combination use group by two-way ANOVA, a synergistic effect was considered to exist.

As a result, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A) showed an additive effect when used in combination with irinotecan hydrochloride, and their combination use showed a superior anti-tumor effect as compared with those obtained with 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or irinotecan hydrochloride alone (Tables 1, 2 and 3, and FIGS. 1, 2 and 3). In addition, combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and irinotecan hydrochloride also showed a remarkable anti-tumor effect that cannot be seen with irinotecan hydrochloride alone (Tables 1, 2 and 3, and FIGS. 1, 2 and 3).

TABLE 1 Relative tumor volume Administered on Day 29 Two-way compound Average ± standard deviation ANOVA Control (untreated) 9.36 ± 2.97 Compound A 3 mg/kg 4.29 ± 1.51 Irinotecan hydrochloride 1.65 ± 0.51 100 mg/kg Compound A 3 mg/kg + 0.97 ± 0.25 p = 0.320 Irinotecan hydrochloride Additive effect 100 mg/kg

TABLE 2 Relative tumor volume Administered on Day 29 Two-way compound Average ± standard deviation ANOVA Control (untreated) 9.36 ± 2.97 Compound A 10 mg/kg 2.93 ± 1.55 Irinotecan hydrochloride 1.65 ± 0.51 100 mg/kg Compound A 10 mg/kg + 0.72 ± 0.11 p = 0.170 Irinotecan hydrochloride Additive effect 100 mg/kg

TABLE 3 Relative tumor volume Administered on Day 29 Two-way compound Average ± standard deviation ANOVA Control (untreated) 9.36 ± 2.97 Compound A 30 mg/kg 1.76 ± 0.92 Irinotecan hydrochloride 1.65 ± 0.51 100 mg/kg Compound A 30 mg/kg + 0.51 ± 0.11 p = 0.0760 Irinotecan hydrochloride Additive effect 100 mg/kg

Tables 1, 2 and 3 show anti-tumor effects obtained by the administration of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A in Tables 1, 2 and 3) alone, the administration of irinotecan hydrochloride alone and the combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and irinotecan hydrochloride in HSC-39 subcutaneous transplanted (xenograft) models. The first day of administration was considered Day 1.

According to the obtained results, the combination of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and irinotecan hydrochloride can provide a pharmaceutical composition and a kit that show a remarkable anti-tumor activity, which may be used for treating cancer.

Example 2 Combination Use of the Compound of the Invention and 5-Fluorouracil in Subcutaneous Transplanted (Xenograft) Models (In Vivo) of Human Scirrhous Gastric Cancer Cell Line (HSC-39)

Human scirrhous gastric cancer cell line HSC-39 (purchased from Immuno-Biological Laboratories Co., Ltd.) was cultured in RPMI1640 (containing 10% FBS) in a 5% carbon dioxide gas incubator at 37° C. to about 80% confluence, and then the cells were collected with trypsin-EDTA. A 5×10⁷ cells/mL suspension was prepared with a phosphate buffer, and each 0.1 mL of the resulting cell suspension was subcutaneously transplanted to nude mice at the side of their bodies.

Thirteen days after the transplantation, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (3, 10 or 30 mg/kg, once a day for four weeks, oral) and 5-fluorouracil (Kyowa Hakko) (50 mg/kg, every four days for three times, intravenous) were administered alone or in combination. The major and minor axes of tumors were measured with Digimatic caliper (Mitsutoyo Corporation), and tumor volumes and relative tumor volumes were calculated according to the following formulae:

Tumor Volume (TV)=Major axis of tumor (mm)×(Minor axis of tumor)² (mm²)/2

Relative Tumor Volume (RTV)=Tumor volume on measurement day/Tumor volume on the first administration day.

If statistically significant interaction was observed in the combination use group by two-way ANOVA, a synergistic effect was considered to exist.

As a result, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A) showed an additive effect when used in combination with 5-fluorouracil, and their combination use showed a superior anti-tumor effect as compared with those obtained with 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or 5-fluorouracil alone (Tables 4, 5 and 6, and FIGS. 4, 5 and 6). In addition, combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and 5-fluorouracil also showed a remarkable anti-tumor effect that cannot be seen with 5-fluorouracil alone (Tables 4, 5 and 6, and FIGS. 4, 5 and 6).

TABLE 4 Relative tumor volume Administered on Day 29 Two-way compound Average ± standard deviation ANOVA Control (untreated) 9.90 ± 3.12 Compound A 3 mg/kg 4.16 ± 1.28 5-Fluorouracil 50 mg/kg 5.16 ± 1.37 Compound A 3 mg/kg + 3.02 ± 0.55 p = 0.150 5-Fluorouracil 50 mg/kg Additive effect

TABLE 5 Relative tumor volume Administered on Day 29 Two-way compound Average ± standard deviation ANOVA Control (untreated) 9.90 ± 3.12 Compound A 10 mg/kg 3.73 ± 1.21 5-Fluorouracil 50 mg/kg 5.16 ± 1.37 Compound A 10 mg/kg + 2.44 ± 0.70 p = 0.413 5-Fluorouracil 50 mg/kg Additive effect

TABLE 6 Relative tumor volume Administered on Day 29 Two-way compound Average ± standard deviation ANOVA Control (untreated) 9.90 ± 3.12 Compound A 30 mg/kg 2.72 ± 1.33 5-Fluorouracil 50 mg/kg 5.16 ± 1.37 Compound A 30 mg/kg + 1.43 ± 0.44 p = 0.887 5-Fluorouracil 50 mg/kg Additive effect

Tables 4, 5 and 6 show anti-tumor effects obtained by the administration of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A in Tables 4, 5 and 6) alone, the administration of 5-fluorouracil alone and the combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and 5-fluorouracil in HSC-39 subcutaneous transplanted (xenograft) models. The first day of administration was considered Day 1.

According to the obtained results, the combination of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and 5-fluorouracil can provide a pharmaceutical composition and a kit that show a remarkable anti-tumor activity, which may be used for treating cancer.

Example 3 Combination Use of the Compound of the Invention and Paclitaxel in Subcutaneous Transplanted (Xenograft) Models (In Vivo) of Human Scirrhous Gastric Cancer Cell Line (HSC-39)

Human scirrhous gastric cancer cell line HSC-39 (purchased from Immuno-Biological Laboratories Co., Ltd.) was cultured in RPMI1640 (containing 10% FBS) in a 5% carbon dioxide gas incubator at 37° C. to about 80% confluence, and then the cells were collected with trypsin-EDTA. A 5×10⁷ cells/mL suspension was prepared with a phosphate buffer, and each 0.1 mL of the resulting cell suspension was subcutaneously transplanted to nude mice at the side of their bodies.

Eleven days after the transplantation, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (3, 10 or 30 mg/kg, once a day for four weeks, oral) and paclitaxel (Calbiochem) (14 mg/kg, once a day for five days, intravenous) were administered alone or in combination. The major and minor axes of tumors were measured with Digimatic caliper (Mitsutoyo Corporation), and tumor volumes and relative tumor volumes were calculated according to the following formulae:

Tumor Volume (TV)=Major axis of tumor (mm)×(Minor axis of tumor)² (mm²)/2

Relative Tumor Volume (RTV)=Tumor volume on measurement day/Tumor volume on the first administration day.

If statistically significant interaction was observed in the combination use group by two-way ANOVA, a synergistic effect was considered to exist.

As a result, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A) showed an additive effect when used in combination with paclitaxel, and their combination use showed a superior anti-tumor effect as compared with those obtained with 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or paclitaxel alone (Tables 7, 8 and 9, and FIGS. 7, 8 and 9). In addition, combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and paclitaxel also showed a remarkable anti-tumor effect that cannot be seen with paclitaxel alone (Tables 7, 8 and 9, and FIGS. 7, 8 and 9).

TABLE 7 Relative tumor volume Administered on Day 29 Two-way compound Average ± standard deviation ANOVA Control (untreated) 10.75 ± 4.94  Compound A 3 mg/kg 3.79 ± 1.43 Paclitaxel 14 mg/kg 4.26 ± 2.06 Compound A 3 mg/kg + 1.54 ± 0.72 p = 0.929 Paclitaxel 14 mg/kg Additive effect

TABLE 8 Relative tumor volume Administered on Day 29 Two-way compound Average ± standard deviation ANOVA Control (untreated) 10.75 ± 4.94  Compound A 10 mg/kg 3.27 ± 1.26 Paclitaxel 14 mg/kg 4.26 ± 2.06 Compound A 10 mg/kg + 1.21 ± 0.42 p = 0.918 Paclitaxel 14 mg/kg Additive effect

TABLE 9 Relative tumor volume Administered on Day 29 Two-way compound Average ± standard deviation ANOVA Control (untreated) 10.75 ± 4.94  Compound A 30 mg/kg 1.69 ± 0.72 Paclitaxel 14 mg/kg 4.26 ± 2.06 Compound A 30 mg/kg + 0.52 ± 0.13 p = 0.555 Paclitaxel 14 mg/kg Additive effect

Tables 7, 8 and 9 show anti-tumor effects obtained by the administration of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide (Compound A in Tables 7, 8 and 9) alone, the administration of paclitaxel alone and the combination use of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and paclitaxel in HSC-39 subcutaneous transplanted (xenograft) models. The first day of administration was considered Day 1.

According to the obtained results, the combination of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and paclitaxel can provide a pharmaceutical composition and a kit that show a remarkable anti-tumor activity, which may be used for treating cancer.

According to the results from these examples, a FGFR2 inhibitor, preferably 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, was found to show an excellent anti-tumor activity when used in combination with a therapeutic substance for gastric cancer, preferably irinotecan, 5-fluorouracil or paclitaxel.

INDUSTRIAL APPLICABILITY

According to the present invention, there is provided a therapeutic agent, a kit and a therapeutic method for undifferentiated gastric cancer that show an excellent anti-tumor activity, use of a FGFR2 inhibitor for producing said therapeutic agent, and a FGFR2 inhibitor for said therapeutic agent.

More particularly, there is provided a therapeutic agent, a kit and a therapeutic method for undifferentiated gastric cancer that show an excellent anti-tumor activity and that can be used for treating undifferentiated gastric cancer by combining:

(i) a FGFR2 inhibitor such as a compound represented by General Formula (I) and a therapeutic drug for gastric cancer;

(ii) a FGFR2 inhibitor such as a compound represented by General Formula (I) and a FGFR2 inhibitor that is not comprised in the compounds represented by General Formula (I); or

(iii) a FGFR2 inhibitor such as a FGFR2 inhibitor that is not comprised in the compounds represented by General Formula (I) and a therapeutic drug for gastric cancer.

The present invention also provides a pharmaceutical composition and a kit for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, a method for treating a disease of said living organism, use of a FGFR2 inhibitor for producing said pharmaceutical composition and a FGFR2 inhibitor for said pharmaceutical composition.

More specifically, there is provided a pharmaceutical composition, a kit and a therapeutic method for said living organism that show an excellent anti-tumor activity and that can be used for treating a disease by combining:

(i) a FGFR2 inhibitor such as a compound represented by General Formula (I) and a therapeutic drug for gastric cancer;

(ii) a FGFR2 inhibitor such as a compound represented by General Formula (I) and a FGFR2 inhibitor that is not comprised in the compounds represented by General Formula (I); or

(iii) a FGFR2 inhibitor such as a FGFR2 inhibitor that is not comprised in the compounds represented by General Formula (I) and a therapeutic drug for gastric cancer. 

1. (canceled)
 2. A therapeutic agent for undifferentiated gastric cancer comprising a compound represented by General Formula (I) below, a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor:

wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of: 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof.
 3. The therapeutic agent according to claim 2, wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof. 4-11. (canceled)
 12. A pharmaceutical composition for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, the pharmaceutical composition comprising a compound represented, by General Formula (I) below, a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor:

wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of: 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof.
 13. The pharmaceutical composition according to claim 12, wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof. 14-21. (canceled)
 22. A method for treating, undifferentiated gastric cancer characterized by administering effective dosages of a compound represented by General Formula (I) below, a pharmacologically acceptable salt thereof or a solvate thereof and a therapeutic substance for gastric cancer or a FGFR2 inhibitor to a living organism:

wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of: 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof.
 23. The therapeutic method according to claim 22, wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof. 24-31. (canceled)
 32. A method for treating a disease, characterized by administering effective dosages of a compound represented by General Formula (I) below, a pharmacologically acceptable salt thereof or a solvate thereof and a therapeutic substance for gastric cancer or a FGFR2 inhibitor to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2:

wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of: 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof.
 33. The therapeutic method according to claim 32, wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof. 34-61. (canceled)
 62. A compound represented by General Formula (I) below, a pharmacologically acceptable salt thereof or a solvate thereof for treating undifferentiated gastric cancer in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor:

a pharmacologically acceptable salt thereof or a solvate thereof, wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of: 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof.
 63. The compound according to claim 62, a pharmacologically acceptable salt thereof or a solvate thereof, wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof. 64-71. (canceled)
 72. A compound represented by General Formula (I) below, a pharmacologically acceptable salt thereof or a solvate thereof for administration in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2:

a pharmacologically acceptable salt thereof or a solvate thereof, wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of: 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof.
 73. The compound according to claim 72, a pharmacologically acceptable salt thereof or a solvate thereof, wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof. 74-80. (canceled)
 81. A kit comprising: (a) at least one selected from the group consisting of a packaging container, an instruction and a package insert describing use of a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor; and (b) a therapeutic agent for undifferentiated gastric cancer comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof:

wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of: 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-(quinolinecarboxamide; 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-(quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof.
 82. A kit comprising: (a) at least one selected from the group consisting of a packaging container, an instruction and a package insert describing use of a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof in combination with a therapeutic substance for gastric cancer or a FGFR2 inhibitor; and (b) a pharmaceutical composition comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2:

wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the ground consisting of: 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof.
 83. A kit characterized by a set of a therapeutic agent for undifferentiated gastric cancer comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof and a formulation comprising a therapeutic substance for gastric cancer or a FGFR2 inhibitor:

wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of: 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof.
 84. A kit used for administration to a living organism comprising at least one selected from the group consisting of a cell overexpressing FGFR2 and a cell expressing mutant FGFR2, the kit characterized by a set of a formulation comprising a compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof and a formulation comprising a therapeutic substance for gastric cancer or a FGFR2 inhibitor:

wherein the compound represented by General Formula (I), a pharmacologically acceptable salt thereof or a solvate thereof is at least one compound selected from the group consisting of: 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof or a solvate thereof. 85-86. (canceled) 